Manejo del dolor con medicamentos Guna

C O M P L E M E N T O S C O N
M E D I C A M E N T O S E U R O L I F E
F E L I P E T O R R E S M D .
M . R . F . , T e r a p i a C e l u l a r
F E L I P E T O R R E S M D .
M . R . F . , T e r a p i a C e l u l a r

E L
D O L O R
R . P . M
M E D I C A M E
N T O S
C O M P L E M
E N T O S

E l d o l o r e s u n a s e n s a c i ó n
s u b j e t i v a , p o l i m o r f a y
m u l t i d i m e n s i o n a l . D i f í c i l d e
c u a n t i f i c a r.
IN T R O D U C C I
Ó N

S E N S A C I Ó N
S U B J E T I V A :
M e z c l a la
p e r c e p c i ó n y la
e s t r u c t u r a
p s i c o l ó g i c a d e l
s u j e t o .
IN T R O D U C C I
Ó N

L a n o c i c e p c i ó n
c o m p r e n d e d o s
e t a p a s :
1 - L a t r a n s d u c c i ó n d e l
e s t í m u l o n o c i v o p o r la s
t e r m i n a c i o n e s n e r v i o s a s
p e r i f é r i c a s
2 - L a t r a n s m i s i ó n d e
e s a s s e ñ a l e s h a c i a e l
s i s t e m a n e r v i o s o
c e n t r a l .
E l im p u l s o n o c i c e p t i v o
s e m o d u l a e n c a d a n i v e l
d e la v í a s e n s i t i v a
F I S I O L O G Í A D E L D O L O R

D I F E R E N T E S T IP O S
D E D O L O R :
- A G U D O : S e
a c o m p a ñ a d e
r e a c c i o n e s
s o m a t o e g e t a t i v a s y
d e a n s i e d a d .
- C R O N I C O ( m á s d e 6
m e s e s ) : S e a c o m p a ñ a
d e t e n d e n c i a s
d e p r e s i v a s ,
i r r i t a b i l i d a d ,
t r a s t o r n o s d e l s u e ñ o ,
d e l a p e t i t o y d e l a
IN T R O D U C C I
Ó N

L o s d o l o r e s s o n c l a s i f i c a d o s , d e
a c u e r d o c o n s u o r i g e n , e n :
C A R A C T E R Í S T I C A S D E L
D O L O R
S O M ÁT I C O S
V I S C E R A L E S
N E U R Ó G E N O

C u a n d o l a s e n s a c i ó n d o l o r o s a s e
p r o d u c e a n i v e l d e l a p i e l , d e l
a p a r a t o l o c o m o t o r o d e l t e j i d o
c o n e c t i v o , s e h a b l a d e d o l o r
s o m át i c o .
Pue d e a d o p t a r 2 f o r m a s :
• D o l o r s u p e r f i c i a l : c u a n d o e l
e s t í m u l o s e l o c a l i z a a n i v e l d e l a
p i e l
• D o l o r p r o f u n d o : e l q u e s e p r o d u c e
a n i v e l m u s c u l a r, ó s e o o d e l t e j i d o
c o n j u n t i v o
S O M ÁT I C O S
D O L O R

E l d o l o r su p e r f i c i al , q u e s e p r o d u c e
p o r e j e m p l o l u e g o d e u n p i n c h a z o ,
s e c o m p o n e d e 2 p a r t e s :
- E l p r i m e r d o l o r s u p e r f i c i a l t i e n e
u n c a rá c t e r a g u d o , e s b i e n
l o c a l i z a d o y d e s a p a r e c e
rá p i d a m e n t e l u e g o d e f r e n a d o e l
e s t í m u l o . E s t e e s t í m u l o d o l o r o s o
s u e l e a c o m p a ñ a r s e d e r e a c c i o n e s
rá p i d a s d e h u i d a , c o m o e l r e t i r a r e l
p i e a l p i s a r u n p e d a z o d e v i d r i o , a
f i n d e e v i t a r m á s d a ñ o s a l
S O M ÁT I C O S
D O L O R

- A e s t e d o l o r s u p e r f i c i a l p r i m a r i o
l e s i g u e a m e n u d o u n d o l o r
s u p e r f i c i a l s e c u n d a r i o , qu e e n
g e n e r a l e s d e c a rá c t e r s o r d o o
u r e n t e , q u e e s m á s d i f í c i l d e
l o c a l i z a r y qu e d e s a p a r e c e m á s
l e n t a m e n t e . E s t e d o l o r s u p e r f i c i a l
s e c u n d a r i o e s n e u r o l ó g i c a m e n t e
i d é n t i c o a l d o l o r p r o f u n d o , q u e
o r i g i n a , p o r e j e m p l o l a c e f a l e a -
u n a d e l a s f o r m a s d e d o l o r m á s
c o m ú n q u e a f e c t a a l o s s e r e s
h u m a n o s .
S O M ÁT I C O S
D O L O R

E l c o n t r a p u e s t o a l d o l o r s o m át i c o e s
e l d o l o r v i s c e r a l .
E s s e m e j a n t e a u n d o l o r d e c a rá c t e r
s o r d o y, j u n t o c o n l a s r e a c c i o n e s d e
t i p o v e g e t a t i v o , a l d o l o r p r o f u n d o .
A p a r e c e p o r f r e n t e a l a d i l a t a c i ó n o
l o s e s p a s m o s (e n e l d o l o r m e n s t r u a l)
d e l a m u s c u l a t u r a l i s a , e n l a s
h e m o r r a g i a s y e n l o s p r o c e s o s
in f l a m a t o r i o s .
S e p u e d e p r e s e n t a r c o m o d o l o r
d u r a d e r o c o m o e n l o s d o l o r e s
e s t o m a c a l e s o d e t i p o p e r i ó d i c o
V I S C E R A L E S
D O L O R

J u n t o a l d o l o r s o m á t i c o y a l v i s c e r a l
s e p u e d e p r e s e n t a r f i n a l m e n t e e l
d o l o r n e u r ó g e n o .
S e o r i g i n a p o r e l e s t í m u l o d e f i b r a s
n e r v i o s a s , c u a n d o l a s m i s m a s s o n
d a ñ a d a s o i n t e r r u m p i d a s ,
p r e s e n t a n d o u n c a r ác t e r a g u d o .
E j e m p l o s d e e s t e t i p o d e d o l o r e s l a
n e u r a l g i a d e l t r i g é m i n o y e l d o l o r
f a n t a s m a l u e g o d e a m p u t a c i o n e s : e l
i n d i v i d u o a f e c t a d o r e f i e r e d o l o r d e l
m i e m b r o a m p u t a d o . E l e s t í m u l o
d o l o r o s o s e o r i g i n a a n i v e l d e l m u ñ ó n
N E U R Ó G E N O
D O L O R

A d e m ás d e s u o r i g e n e l d o l o r p u e d e
d i f e r e n c i a r s e d e a c u e r d o c o n s u
d u r a c i ó n :
D O L O R
A G U D O
C R Ó N I C O

El d o l o r agu d o t i e n e u n t i e m p o
l i m i t a d o , d e s a p a r e c i e n d o
rá p i d a m e n t e . E s t e d o l o r p u e d e
t o l e r a r s e i n c l u s o s i n m e d i c a m e n t o s
c o m o e n l o s t r a t a m i e n t o s
o d o n t o l ó g i c o s .
A G U D O
D O L O R
El d o l o r c r ó n i c o p u e d e p r e s e n t a r s e
c o m o d u r a d e r o e n e l d o l o r l u m b a r o
t u m o r a l o r e c u r r e n t e c o m o e n l a s
c e f a l e a s o a n g i n a d e p e c h o ) . L o s
d o l o r e s c r ó n i c o s s o n e n g e n e r a l
d i f í c i l e s d e t o l e r a r.
C R Ó N I C O

N o t o d o s lo s d o l o r e s t i e n e n s u o r i g e n
e n lo s r e c e p t o r e s d o l o r o s o s :
D O L O R
PS I C Ó G E N O

A v e c e s p u e d e p r e v a l e c e r u n a
a f e c c i ó n p s i c o l ó g i c a , e n l a c u a l e l
p a c i e n t e n o p u e d e m a n i f e s t a r s u s
c o n f l i c t o s d e o t r a m a n e r a q u e
r e f i r i e n d o d o l o r e s .
L a a f e c c i ó n p s i c o l ó g i c a p u e d e
p r e s e n t a r s e b a j o u n a f o r m a
s o m át i c a , c o m o u n d o l o r.
PS I C Ó G E N O
D O L O R

IN T R O D U C C I Ó N
MECANISMOS PERIFERICOS:
SENSIBIL IDAD PUNTUAL DE L A PIEL
E l exá m e n d e l a s e n s i b i l i d a d d e l a
p i e l a e s t í m u l o s m u y l o c a l i z a d o s
p e r m i t e o b s e r v a r q u e l a s e n s i b i l i d a d
v a r í a d e u n p u n t o a o t r o; m u y b a j a e n
a l g u n o s p u n t o s y m u y e l e v a d a e n
o t r o s .
T a m b i é n s e h a p o d i d o e s t a b l e c e l a
e x i s t e n c i a d e p u n t o s c u tán e o s q u e
r e s p o n d e n a l t a c t o , a l f r í o , a l c a l o r y
a a l d o l o r.
Pa r a c a d a t i p o d e s e n s a c i ó n s e h a n
d i b u j a d o m a p a s p a r a c a d a r e g i ó n

INTERVENCIONES TERAPÉUTICAS:
NIVEL PERIFÉRICO
E n c a d e n a m i e n t o n e u r o n a l
r e s p o n s a b l e d e la
t r a n s m i s i ó n d e la
in f o r m a c i ó n a lo s c e n t r o s
IN T R O D U C C I Ó N

E x i s t e n u n a c a t e g o r í a d e r e c e p t o r e s
q u e n o p u e d e n s e r e s t i m u l a d o s m á s
q u e p o r e s t í m ulo s i n t e n s o s d e o r i g e n
d i v e r s o s . E s t a s e s t i m u l a c i o n e s
p u e d e n s e r r e a l i z a d a s e n t r e s
c o n d i c i o n e s :
1 - L e s i ó n t i s u l a r o r i g i n a d a p o r
p u n c i ó n , p r e s i ó n , r o t u r a o
qu e m a d u r a .
2 - I n f l a m a c i ó n t i s u l a r c o n s e c u e n t e
d e l a s a n t e r i o r e s o d i r e c t a m e n t e
p r o v o c a d a p o r a g e n t e s q u í m i c o s
e xó g e n o s o e n d ó g e n o s .
N O C I C E PT O R E S

N O C I C E PT O R E S
A p e s a r d e l a d i v e r s i d a d d e l o s
e s t í m u l o s , e s p o s i b l e h a b l a r d e
n o c i c e p t o r e s d e l a n t e d e l o s c r i t e r i o s
s i g u i e n t e s (definidos por Iggo):
U mb r al a e s t í m ul o s e l e v a d o : e s t o s e
a p l i c a , s o b r e t o d o , a
n o c i c e p t o r e s m e c á n i c o s o t é r m i c o s
c u y o u m b r a l e l e v a d o
c o n t r a s t a c o n e l u m b r a l b a j o d e l o s
m e c a n o o d e lo s
t e r m o r e c e p t o r e s e s p e c í f i c o s .
Pequ eñ a su p e r f i c i e d e l c a m p o
r e c e p t o r.
D e s c a rg a d e t i p o t ó n i c o , p o c o
a d a p t a b l e , p e r s i s t e n t e d e s p u é s
d e la p a r a d a d e l e s t í m u l o .
I n e r v a c i ó n p o r f ib r a s d e p e qu eñ o
d i ám e t r o (A d e l t a y C ).

S U S T A N C I A S A L G O G E N A S
KININAS: S o n u n g r u p o d e s u s t a n c i a s
q u e t a m b i é n a c t ú a n c o m o
m e d i a d o r e s d e la in f l a m a c i ó n :
- BRADIKININA: S e l i b e r a e n l a s
q u e m a d u r a s c u tá n e a s . L a
i n y e c c i ó n l o c a l e n e l h o m b r e
p r o v o c a d o l o r p o r a d e s c a r g a d e
la s f i b r a s C .
- PROSTAGANDINAS: L a P G E l y PG E 2 ,
i n t e r v i e n e n d e m a n e r a e v i d e n t e
e n l a i n f l a m a c i ó n . L a s
p e r f u s i o n e s s u b c u tá n e a s d e PG E 1
a m u y b a j a s c o n c e n t r a c i o n e s e n
e l h o m b r e p r o d u c e n

IM A N E S
T E R A PE U T I C O S

NIVEL PERIFERICO: Co n n ut r i e n t e s :
- N u t r i e n t e s qu e in h i b e n la s
c i t o qu i n a s , p r o s t a g l a n d i n a s
y le u c o t r i e n o s .
- N u t r i e n t e s qu e in t e r v i e n e n e n la
r e p a r a c i ó n d e lo s t e j i d o s d a ñ a d o s
p o r la in f l a m a c i ó n .
- N u t r i e n t e s d e a p o y o a n t i o xi d a n t e .
IN T E R V E N C I O N E S
T E R A PÉU T I C A S

S i g u i e n d o la r e a c c i ó n d e B y s t a n d e r
IN T E R V E N C I O N E S
T E R A PÉU T I C A SN I V E L PE R I F E R I C O : C o n C o m p l e j o s Ho m e o

InmunologiaInmunologia
L a inflamación periférica es regulada por el
S .N .C .
L a a f i n i d a d d e l T C R , p o r lo s
c o m p l e jo s p e p t íd i c o s a s o c i a d o s a l
M H C , a u m e n t a e n la m e d i d a e n
qu e lo s c o n t a c t o s s e a n m a s
r e p e t i t i v o s .

E l in t e r f e r o n ( I F N ) s e g a m a o
b e t a s e p r o d u c e n b ás i c a m e n t e
p o r e l e s t i m u l o d e a n t i g e n o s
v i r a l e s .
E l M A L T
s e c r e t a
T G F b e t a -
1 , qu e
in d u c e la
p r o d u c c i ó
n le
li n f o c i t o B
e Ig A .
E l T N F - a l f a
y la IL - 1 e s
e s t i m u l a d o s
p o r
li p o p o l i s a c a
r i d o s
b a c t e r i a n o s
y e n m e n o r
e s t ím u l o s
a n t i g e n o s
v i r a l e s .

S e p u e d e s u f r i r e l s ín d r o m e
d e la s m u c o s a s p a r c i a l o
t o t a l m e n t e , s e g ún e l n u m e r o
d e m u c o s a s
c o m p r o m e t i d a s .

E l M A L T , s e
c o n s i d e r a u n
ór g a n o li n f o i d e
e n t r e la s
m u c o s a s , e n la s
qu e in t e r v i e n e n
la s m u c o s a s
r e s p i r a t o r i a s y
d i g e s t i v a s , e l T G U
c o m p a r t e d r e n a je
y la p r e s e n c i a d e
t e ji d o li n f o i d e
s i m i l a r a l
in t e s t i n a l .
E l f e n óm e n o d e
H o m i n g d e lo s
le u c o c i t o s , o
v o l v e r a l s i t i o
d e
s e n s i b i l i z a c i ón
a n t i g én i c a ,
e x p l i c a la
m a n i f e s t a c i ón
f i s i o p a t o l o g i c a
d e l s ín d r o m e d e
la s m u c o s a s

P s i c o n e u r o e n d o c r i n o i n m u n o l o g
ia : in t e r a c c i ón e n t r e lo s
s i s t e m a s n e u r o e n d o c r i n o e
in m u n e , a s í c o m o e l e s t u d i o d e
lo s c a m b i o s c o n d u c t u a l e s qu e
d i c h a in t e r a c c i ón p r o d u c e .
L a in t e r a c c i ón e s
b i d i r e c c i o n a l

In f l u y e la
m e n t e e n la
s u s c e p t i b i l i
d a d d e
e n f e r m a r , o
e n la
f a c i l i d a d
p a r a
r e c u p e r a r s e
d e u n a
e n f e r m e d a
d ?
E l c e r e b r o
y la
r e s p u e s t a
i n m u n e
E l c e r e b r o
y la
r e s p u e s t a
i n m u n e
L e s i o n e s d e l
h i p o t ál a m o ,
s i s t e m a li m b i c o ,
o f o r m a c i ón
r e t i c u l a r
L e s i o n e s d e l
h i p o t ál a m o ,
s i s t e m a li m b i c o ,
o f o r m a c i ón
r e t i c u l a r
L a t e r a l i z a c i ón
h e m i s f ér i c a d e la
r e s p u e s t a
in m u n e
L a t e r a l i z a c i ón
h e m i s f ér i c a d e la
r e s p u e s t a
in m u n e

Sustento inmunológicoSustento inmunológico

Sustento inmunológicoSustento inmunológico
Clonación en
ganglios
linfáticos.
Son atraídos por
quimiotaxis o por
organotropismo o
histotropismo.

NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
ES EL CAMPO
CIENTÍFICO
INTERDISCIPLINARIO
QUE INVESTIGA LAS
RELACIONES ENTRE EL
CEREBRO ( MENTE-
CONDUCTA) Y EL
SISTEMA INMUNE Y
SUS CONSECUENCIAS
CLINICAS

NeuroendocrinoinmunologiaNeuroendocrinoinmunologia

This material is based on the presenter’s
studies in PHYSIOLOGICAL REGULATING
MEDICINE.
The information presented here is not to be
considered a prescription and we do not
accept medical or legal responsibility for
misuse of the information presented. This
information is for educational purposes for
licensed health care professionals within their
scope of practice.
43
© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .

1 . L O W D O S E S .K.A . - P R I N C I P L E S
O F HO M E O P A T HY
1 . N E W C HE M I C A L S WIT H S .K.A .
T E C HO N O L O G Y
1 . C YT O KI N E S : IT S R E L E VA N C E IN
P A I N A N D IN F L A M M A T I O N
1 . E XP E R I M E N T A L D A T A T O
VA L I D A T E C YT O KI N E P O T E N C Y
I N A N I M A L M O D E L
1 . C L I N I C A L A P P L I C A T I O N O F L O W
D O S E S .K.A . IN P A I N
What You Will L earn T oday

WE S T E R
N
C O N VE N
T I O N A L
M E D I C I
N E
C O M P L E M
E N T A R Y
A L T E R N A T
I VE
M E D I C I N E
P h y s i o l o g i c a l
R e g u l a t i n g M e d i c i n e
P R M
45
G u n a S . p . a .

Homeopathic S cience M olecular Biology
M I N E R A L ,
P L A N T ,
A N I M A L
D E R I VA T I VE
S
N E U R O P E P
T I D E S ,
C YT O KI N E S ,
HO R M O N E S ,
G R O WT H
F A C T O R S
P R M D R U G S
A new pharmacological concept: one
biotherapeutic medicine blending synergistic
ingredients from Complementary Alternative
Medicine and Conventional Medicine to achieve
a positive clinical outcome.
G u n a S . p . a .

PHY SI OL OG I CA L REG U L A TI NG MEDICI NE (PRM)
T he science of P R M integrates state of the art scientific
advances in:
• Homeopathy
• Homotoxicology
• P sycho N euro E ndocrine Immunology
(P N E I )
• N utritional and P hyto- M edicine
To formulate biotherapeutic medicines achieving the best
individualized prescription for patients to promote recovery
from illness and restoration of health
P .N .
E .I .
M o l e
c u l a r
Bio l o
g y
N u t r i
t i o n a l
M e d i
c i n e
H o m e
o p a t h
y
H o m o t o
x i c o l o g y
Qu a n
t u m
P h y s
ic s
©DipartimentoScientifico
GunaS.p.a.

P
N
E
I
C E N T R A L
N E R VO U S
S YS T E M
&
N E U R O VE G E T A T I
VE S YS T E M S
I M M U N E
S YS T E M
E N D O C R I N E
S YS T E M
Homeostatic control systems
G u n a S . p . a .
A d e r , R . , P s y c h o n e u r o i m m u n o l o g y , IV e d i t i o n , v o l . 1
e 2 , A c a d e m i c P r e s s , A m s t e r d a m 2 0 0 7.
It is th e c l a s s i c a l te x t o n t h e m a t t e r , p u b b l i s h e d f o r

D a : P s i c o N e u r o E n d o c r i n o I m m u n o l o g i a . F r a n c e s c o
Bo t t a c c i o l i – R E D E d i z i o n i

 T h e h o r m o n e s in f l u e n c e
c y t o k i n e s le v e l s a n d
r e a l i z e a c o n n e c t i o n
b e t w e e n e n d o c r i n e s y s t e m
a n d im m u n e s y s t e m
◦ F E M A L E S E XU A L H O R M O N E S
in h i b i t t h e T h 2 r e a c t i o n a n d
s t i m u l a t e T h 1 c y t o k i n e s
◦ C O R T I S O L i n h i b i t t h e T h 1
r e a c t i o n a n d i n p a r t i c u l a r IL -
2 . In t u r n , d i f f e r e n t
in t e r l e u k i n s , a m o n g w h i c h IL -

◦ IL - 1 , T N F - α, IF N - γ
a n d in p a r t i c u l a r IL -
6 h a v e a
f u n d a m e n t a l r o l e in
t h e t h y r o i d f u n c t i o n :
t h e y in h i b i t t h e
io d i d e u p t a k e
o r g a n i f i c a t i o n , t h e y
h i n d e r t h y r e o c y t e s
g r o w t h ,
t h y r e o g l o b u l i n
s y n t h e s i s a n d t h e
r e l e a s e o f t h y r o i d
h o r m o n e s , h e p a t i c
d e i o n i z a t i o n w h i c h
in t u r n a c t i v a t e s T 4
t o T 3
◦ IL - 1 β a n d T N F - α
in h i b i t T R H ,

P
N
E
I
PNEI
P S Y C H
E
S O M
A
P S Y C H
E
P. N. E. I. NETWORK AND
MES S ENG ER MOLECULES
G u n a S . p . a .
IN T E R L E U K I
N S
H O R M O N E
S
N E U R O P E P T I
D E S
H O R M O N E
S

M e s s e n g e r
M o l e c u l e s
T h e F o u n d a t i o n f o r
P R MC O M M UN I C AT I N G
M O L E C UL E S a r e
m e s s e n g e r s , t h e wo r d s
u s e d b y t h e 3
h o m e o s t a t i c c o n t r o l
s y s t e m s t o s p e a k e a c h
o t h e r … a n d t o
u n d e r s t a n d e a c h o t h e r .
G u n a S . p . a .
5
3

EVERY D IS EAS E IS THE
EXPRES S ION, THE CONS EQUENCE
OF CHANG ED CONCENTRATION
OF MES S ENG ER MOLECULES
G u n a S . p . a .
54
P. N. E. I. NETWORK AND
MES S ENG ER MOLECULES

P
N
E
I
PNEI
P S YC H
E
S O M
A
P S YC H
E
M O S C HU S
N U X VO M I C A
N E U R O P E P T I D E S
HO R M O N E S
IN T E R L E U KI N S
THE P. N. E. I.
NETWORK
G u n a S . p . a .

P
N
E
I
PNEI
P S YC H
E
S O M
A
P S YC H
E
THE P. N. E. I.
NETWORK
G u n a S . p . a .
IN T E R L E U
KIN S
HO R M O N E
S
N E U R O P E P T
ID E S
HO R M O N E
S

H E A L T H
P HYS I O L O G I C A L
C O N C E N T R A T I O N
D I S E A S E
D I S E A S E
HYP O - C O N C E N T R A T I O N
HYP E R - C O N C E N T R A T I O N
1 0
- 6
1 0-
1 5
G u n a S . p . a .
4C – X6

g (gr a m )= 1
10 -1 = 0.1
10 -2 = 0.01
m g (m i lli gr a m )= 10 -3 = 0.001
μg (m i c r o gr a m )= 10 -6 = 0.000001
n g (n a n o gr a m )= 10 -9 = 0.000000001
p c g (p i c o gr a m )= 10 -12 =
0.000000000001
f g (f e n t o gr a m )= 10 -15 =
0.000000000000001
D E F I N I T I O N S
G u n a S . p . a .

P R M
P R M c o d i f i e s t h e v i s i o n
o f t h e p h y s i o l o g i c
m i l i e u o f t h e o r g a n i s m
a s a p s y c h o - n e u r o -
e n d o c r i n e - i m m u n e
N E T W O R K r e g u l a t e d
b y m e c h a n i s m s o f
F I N E C O N T R O L
( s e n s i t i v e li g a n d -
r e c e p t o r c o n t r o l
m e c h a n i s m s )
G u n a S . p . a .
59

R e g u l a t i n g M e d i c i n e :
… a d y n a m i c n e w
c o n c e p t
P R M m o v e s f r o m
c l a s s i c a l Ho m e o p a t h y t o
t h e r e v o l u t i o n a r y
t h e r a p e u t i c c o n c e p t o f
r e s t o r i n g p h y s i o l o g y
t h r o u g h a d m i n i s t r a t i o n
o f c o m m u n i c a t i n g
m o l e c u l e s - h o r m o n e s ,
i n t e r l e u ki n s ,
n e u r o p e p t i d e s a n d
g r o wt h f a c t o r s -
p r e p a r e d in
6 0
G u n a S . p . a .

P R M
T h e h o m e o p a t h i c
p r e p a r a t i o n m e t h o d o f
“d i l u t i o n - d y n a m i za t i o n ”
m a ke s t h e s e
c o m m u n i c a t i n g
m o l e c u l e s e v e n m o r e
e f f e c t i v e .
6 1
G u n a S . p . a .

6 2
T
M
1
0 -
3
1 0
- 6
1 0-
1 5
M I N I M A L E F F E C T I VE
P HA R M A C O L O G I C A L D O S E
T O XI C
CO N CE N T R A T I O
N
m g / m l
P H A R M A CO L O G I CA L
CO N CE N T R A T I O N
m c g / m l
P HYS I O L O G I C A L
C O N C E N T R A T I O N
ng- pcg/ml
T O XI C
E F F E CT
S I D E
E F F E CT S
WIT HO U T
D YN A M I ZA T
IO N : N O
BIO L O G I C A
L
O r
P HYS I O L O G I
C A L
E F F E C T S
P H A R M A CO L O
G I CA L E F F E CT S
WIT H
D YN A M I ZA T
IO N :
P HYS I O L O G I
C A L
E F F E C T S
E F F E C T S O F D I F F E R E N T D O S E S O F
C YT O KI N E S
M I N I M A L E F F E C T I VE P HYS I O L O G I C A L
D O S E
G u n a S . p . a .

DYN AM I ZAT I O N =S.K .
A.
S. Se qu e n t i a l
K . K i n e t i c
A. Ac t i v a t i o n
G u n a S . p . a .

• Hypothalamus
–S o m a t o s t a t i n e
–Be t a -
E n d o r p h i n
• Hypophysis
–F S H
–L H
–A CT H
–P r o l a c t i n
–T S H
• P ineal G land
–M e l a t o n i n
• T hyroid
–T S H
–T r i i o d o h y r o
n i n e ( T 3 )
–T h y r o x i n e
( T 4)
–Ca l c i t o n i n
• P arathyroids
–P a r a t h o r m o
n e ( P T H )
• O vary
–Be t a -
E s t r a d i o l
–P r o g e s t e r o n
e
G u n a S . p . a .

Neuropeptides of PRM
• H y I p o t h a l a m u s e
H y p o p h y s i s
– Be t a - E n d o r f i n
• N u c l e u s o f r a f e o f B u l b o ,
o f B r i d g e a n d o f
M e s e n c e f a l o . S t o m a c h
a n d b o w e l
– S e r o t o n in
• P i n e a l G l a n d
– M e l a t o n i n
G u n a S . p . a .

6 66 6
E ffects of different doses of I L -
1 - β on isolated human fibroblasts
© D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
in c o o p e r a t i o n wit h:

6 8
G u n a S . p . a .

E xpression of N F Kb and
c- fos on isolated
fibroblasts
c - f o s
1 h 1 8h
lp s a c d b
1 h
n f k b
lp s a c
1 8h
lp s a c d blp s a c
G u n a S . p . a .

E xpression of N F Kb and c-
fos on isolated fibroblasts
Legend
• lps=control
• A =placebo (water and alcohol)
• B=pharmacological concentration
• C =4C H diluted and dynamized
• D =4C H only diluted but not
dynamized
G u n a S . p . a .

71
71
T h1 T h2
T HE I M M U N E
S YS T E M

72
72
T h- 1 /T h- 2
BA L A N C E
IL - 4
IL - 5
C rohn’s
P soriasis
A sthma
A topy
IL - 1 2
IF N - T h- 1
T h- 2
T h- 2
T h- 1
IL - 1 2
IF N - 
IL - 4
IL - 5

Th2
Th1
…in A llergy

T h
0
T h
2
T h
1
I N F - γ, IL -
1 2
I L - 4
IN H I BI T
S
S T I M U L
A T E S
S T I M U L
A T E S
IN H I BI T
S
IL -
1 2
IN F
- γ
THE CONCEPT OF BALANCE
D eveloping Th subsets results in cross -regulation. While I L - 4
stimulates Th2 differentiation and inhibits diffentiation of Th 1
cells, I L - 1 2 and I F N - γ stimulates Th 1 differentiation and
inhibits the development of T h2 cells.
Cooke , A. Th17 in Inflammatory Conditions. 2006, Rev Diabetic Stud 3: 72-7
- Bettelli E. et al. Th17: The third member of the effector T cell trilogy. Current Opinion in Immunology 2007, 19:
652-657
IL -
4

75
75
T h1
I L - 1 2
I F N - 
T h2
IL - 4
IL - 5
A S T HM A
T he interleukins are able to
rebalance the I mmune S ystem in
A llergy

76
76
T h1
IL - 1 2
IN F - 
T h2
IL - 4
IL - 5
Healing from A sthma

7777
E ffects of low dose cytokines in
treatment of inflammatory
pathologies: use in an animal
model of allergic asthma
in c o o p e r a t i o n wit h:

E XP E R I M E N T A L P R O T O C O L
D A Y 1
In je c t i o n
o f 1 m g
o f e g g -
a l b u m i n
+ 5 m g
A l ( O H )3
in P BS ( I P )
D A Y 7
In je c t i o n
o f 1 m g
o f e g g -
a l b u m i n
+ 5 m g
A l ( O H )3
in P BS ( I P )
D A Y 1 3
A e r o s o l
o f 1 m g
o f e g g -
a l b u m i n
+ 5 m g
A l ( O H )3
in P BS
f r o m D A Y 1 8 u n t i l D A Y 3 8
Blo o d d r a w i n g
T R E A T M E N T WIT H IL -
1 2 +I F N - γ
L U C KY
M O U S
E
A L L E R
G I C
M O U S E
D A Y 2 7
In je c t i o n
o f 1 m g
o f e g g -
a l b u m i n +
5 m g
D A Y 3 0
5% e g g -
a l b u m i n
in P BS 0 ,5.
( A e r o s o l )
D A Y 38
Bronchoalveolar
lavage fluid

0
1
0
2
0
3
0
4
0
5
0
6
0
[IL-4](pcg/ml)
0
2
0
4
0
6
0
8
0
1 0
0[IL-5](pcg/ml)
1 2
0
1 40
1 6
0
1 80
U N T R O VA U N T R O VA
BA L F – after treatment with egg albumin and A l (O H)3
A sthma© D i p a r t i m e n t o
T h
2
T h
1
Legend
• 1 - U ntr=healthy
mouse
• 2- O VA =allergic
mouse

P rotocol G roups to test efficacy of
treatment with 2 anti- allergic
interleukins in combination (IL -
1 2+I F N - γ) in the allergic mouse
Legend
• 1 - U ntr- - healthy mouse
• 2- O VA - - allergic mouse
• 3- O VA +A L L O - - I L - 1 2+I F N - γ
in pharmacological concentration
• 4- O VA +4CH- - I L - 1 2+I F N - γ in
physiological concentration (4CH) dilution
and dynamized
• 5- O VA +4CHn- - I L - 1 2+I F N - γ in
physiological concentration (4CH) dilution© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .

Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH
0
10
20
30
40
50
60
70
IL-4pg/ml
0
20
40
60
80
100
120
140
160
180
IL-5pg/ml
L evel of IL - 4 and IL - 5 in
mice sera
on day 7th of treatment
1 2 3 4 5
1 2 3 4 5
T reatment plan of allergic mouse with the 2
anti- allergic interleukines in association
(IL - 1 2+I F N - γ)
Legenda
• 1 - U ntr=healthy mouse
• 2- O VA =allergic mouse
• 3- O VA +A L L O =I L - 1 2+IF N - γ in
pharmacological concentration
• 4- O VA +4CH=IL - 1 2+I F N - γ in
physiological concentration (4CH) diluted and
dinamized
• 5- O VA +4CHn=IL - 1 2+IF N - γ in
physiological concentration (4CH) only diluted but
not dinamized
L evels of IL - 4
L evels of IL - 5

0
500
1000
1500
2000
2500
IL-12pg/ml
0
1000
2000
3000
4000
5000
6000
IFNgammapg/ml
L evel of IL - 1 2 and IN F - γ
in mice sera
on day 7th of treatment
1 2 3 4 5
1 2 3 4 5
T reatment plan of allergic mouse with the 2
anti- allergic interleukines in association
(IL - 1 2+I F N - γ)
Legenda
• 1 - U ntr=healthy mouse
• 2- O VA =allergic mouse
• 3- O VA +A L L O =I L - 1 2+IF N - γ in
pharmacological concentration
• 4- O VA +4CH=IL - 1 2+I F N - γ in
physiological concentration (4CH) diluted and
dinamized
• 5- O VA +4CHn=IL - 1 2+IF N - γ in
physiological concentration (4CH) only diluted but
not dinamized
L evels of IL - 1 2
L evel of IF N - γ

p gp gf gf g
U nit of measurement…
…the mistery… that is not a
mistery
4CH
we give… …we detect in
the blood

U N T R E A T E D 0
O V A=C O N T R O L (A L L E R G I C
M O U S E )
2 0 , 188±0 , 6 1 3
OVA + A L L O (P H A R M A C O L O G I C A L
T R E A T M E N T )
0
OVA + 4 C H (4 C H S K A - A C T IVIT E D
T R E A T M E N T )
0
O V A+4 C H n (4 C H n o t - SKA -
A C T I V I T E D T R E A T M E N T )
19,567±0 , 685
O V A+3 0 C H (3 0 C H SKA - A C T I V I T E D
T R E A T M E N T )
2 0 ,788±0 , 4 1 6
Number of cells expressed in cells/BALF (x1 04)
E osinophil numbers in
mouse BA L F
(bronchoalveolar lavage fluid)
on day 20 of treatment

IL-12
0,00
5,00
10,00
15,00
20,00
25,00
30,00
Untr OVA+100ng/die OVA+4CH din
[IL-12](pg/ml)
0
5
10
15
20
25
30
35
40
45
50
Untr OVA+100ng/die OVA+4CH din
[IFNgamma](pg/ml)
IFN-g
S afety of clinical use of S KA
treated low doses of interleukines
P reliminary datas

PRM
ANTI AG ING
THERAPIES
G u n a S . p . a .
8
6

Ivo BIANCH I M.D. ©
E L D E R L Y
P e o p l e
L o w R e a c t i v i t y
Ce l l
S t i m u l a t i o n
G U N A Ce l l
T i s s u e
G U N A M a t r i x
H o r m o n a l
G U N A
F e m a l e / M a l e
Im m u n e
Cit o m i x
H i g h L e v e l o f
In t o x i c a t i o n
D r a i n a g e
G e n e r i c
S p e c i f i c
H i g h L e v e l o f
In f l a m m a t i o n
A n t i
In f l a m m a t i o n
G U N A F l a m
IL - 1 0

• G U N A - F E M / M A L E :
2 0 d r o p s tw i c e a
d a y fo r 2 - 4 m o n t h s
+
G U N A - F L A M : 2 0
d r o p s tw ic e a d a y
fo r 2 - 4 m o n t h s
• M E L A T O N I N 4 C H : 2 0
d r o p s a t e v e n i n g
e v e r y d a y fo r 2 - 4
m o n t h s
+
• IG F 1 4 CH : 2 0 d r o p s a t
e v e n i n g e v e r y d a y fo r
2 - 4 m o n t h s (anti-neoplastic
and anti-oxidant action)
• IL 2 4 CH : 2 0 d r o p s
t w ic e a d a y fo r 2 - 4
m o n t h s (it is the “amti-aging
interleukine)
• CE R E B R U M CO M P . :
1 a m p o u l e v r y 2
d a y s fo r 2 - 4 m o n t h s
(elderly people)
• G U N A -
G E R I A T R I CS :
2 0 d r o p s
t w i c e a d a y
fo r 2 - 4
m o n t h s
A N T I A G I N G G E N E R A L
S T R A T E G Y
• G U N A - M A T R I X:
2 0 d r o p s tw i c e a
d a y fo r 2 - 4
m o n t h s
+
• G U N A - CE L L : 2 0
d r o p s tw ic e a d a y
fo r 2 - 4 m o n t h s
G u n a S . p . a .
88

T r o p h i c
e f f e c t
A n t i a g i n g
Ca t a b o l i c
e f f e c t
A n t i c a n c e r
M e l a t o n i n
T 3
S o m a t o s t a t i n
IG F - 1
D H E A
G H

 I n a n i m a l s lo n g l i f e is
c o r r e l a t e d w i t h :
◦H i g h l e v e l s o f :
I G F - 1
M e l a t o n i n

Ma t r i x
liqu i f i c a t i
o n a n d
dr a i n a ge
Ac t i o n
a ga i n st t o xi n
im p r e gn a t i o
n
Lym p ha t i
c
dr a i n a ge
•S t i m u la t i o n o f
m i t o c ho n dr i a l
e n e r gy
p r o du c t i o n . *
•Ma t r i x
a c i di f i c a t i o n
(p r o m o t i n g
c o n n e c t i ve t i ssu e
r e a c t i vi t y). **
•Ac. D-L malicum 6X*
•Natrium oxal. 6X*
•Natrium pyruv. 6X*
•NADID 6X*
•Trychinoil 6X*
•Vit. C 2X*
•Ac. L(+) lacticum3X**
•D e a c t i va t i o n
(thr o u gh
in f la m m a t i o n ) a n d
n e u t r a li za t i o n o f
t he im p r e gn a t e d
t o xi n s*.
•S yn e r gi st i c a c t i o n
wit h Fu c u s a n d
t hyr o i d ho r m o n e
a c t i va t i n g the
sym p a t he t i c o t o n i c
n e r vo u s syste m **.
•Pyrogenium 12X*
•Fucus 3X*
•Tyrosine 2X**
•Phenilalanine 2X**
•Histidine 2X**
•In a c t i ve t o xi n s
m o bi li ze d t o wa r ds
t he lym p ha t i c c i r c le
f o r dr a i n a ge
•Lymphatic vessel 6X
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he
c o n st i t u t i o n a l
t e n de n c y t o
im p r e gn a t i o n o f t he
m a t r i x wit h t o xi n s a n d
t o t he de ve lo p m e n t o f
Dysmetabolic Mesenchymopathy
(psychcosis).**
•Ma t r i x
•Hyaluronidase 6X*
•Thuja 6/8/12/30/200X**
•Natrium sulfuricum 6/8/12/30/200X **
•Prolactine 6X***
•DHEA 6X***
•In c r e a se o f
Fu n da m e n t a l
S u bst a n c e kin e t i c s
(p r o t e i n hydr o lysi s,
hyp e r -i o n i c i t y,
hist a m i n i c a c t i vi t y,
in c r e a se d
t e m p e r a t u r e ) a n d
m a t r i x t u r n o ve r
r a t e . *
•S ym p a t he t i c o t o n i c
•IL 6 4C*
•DHEA 6X*
•Pyrogenium 12X*
•Conjunctive Tissue 6X*
•Tyrosine 2X**
•Histidine 2X**
•Prolactine 6X***
G UNA-
MATRIX
G u n a S . p . a .
9
1

• Mo du la t i o n o f t he n e u r o ge n i c
p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -
e n do r p hi n p e r i p he r a l
r e c e p t o r s**.
• RES st i m u la t i o n a n d
hin dr a n c e t o t he
p o ssi ble se p t i c
p r o gr e ssi o n o f the
in f la m m a t o r y
p r o c e ss.
The 3 p i lla r s… i n a
dr u g
G UNA-FLAM
G u n a S . p . a .
Ac o n i t u m *
Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *
Ap i s*
Br yo n i a *
Pyr o ge n i u m *
Phyt o la c c a *
Na t r i u m p yr u vi c u m *
Ac i du m c i t r i c u m *
Cu -glu c o n a t e *
An t i IL 1-a lf a **
TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the
n e u r o ge n i c , va sa l
e xu da t i ve p ha se s
o f the
p r o c e ss*.
• Hin dr a n c e t o the
in f la m m a t i o n
st a r t p o i n t **.
• Po t e n t i a t i o n o f
t he im m u n o lo gi c
a n t i -
a c t i vi t y ha vi n g Th2-
Th3 p o la r i t y***.
Ac o n i t u m *
Be t a -e n do r p hi n **
He p a r su lf u r i s
Pyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4C
Hyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6X
Co n ju n c t i ve t i ssu e 12X
• Re gu la t i o n o f
t he e xt r a c e llu la r
m a t r i x fu n c t i o n
t hr o u gh t he
m o du la t i o n o f
t he hyp o p hysa r y
ho r m o n s a c t i o n
a n d the p i n e a l
gla n d
st i m u la t i o n .

G UNA CELL
Vit a m i n s
In c r e a se o f
e n e r ge t i c
m e t a bo li sm .
Co e n zym e a c t i vi t y
p e r f o r m i n g c a t a lyt i c
a c t i o n o n c e ll f u n c t i o n s.
Ca t a lyt i c
a c t i o n o n
e n zym e
f u n c t i o n s.
• Ca r r i e r a c t i o n *.
• Re p r o gr a m m i n g o f c e ll
f u n c t i o n **.
• 2n d f u n c t i o n
m e sse n ge r ***.
-lip o i c -a c . 3X
S u c c i n i c . a c . 3X
Fu m a r i c . a c . 3X
Me t hyglyo xa l 10X
Vit . E
Vit . C
Vit . B1, B2, B3, B5,
B6, B9, B12
Co lc hi c u m 6/12/30X
Co n i u m 6/12/30X
Po do p hyllu m 6/12/30X
Me t hyglyo xa l 10X
An t i -
de ge n e r a t i ve a n d
a n t i -a gi n g
a c t i o n .
Ac . -L-c a r n i t i n e * 2X
D NA** 6X
RNA** 6X
Co lli n so n i a 2X***
c AMP 6X***
Mn -glu c . 3X
Mn -p ho sp h. 6X
Mg-p ho sp h. 3X
P 4X
Ca -glu c . 3X
Fe f u m a r . 3X
S 3X
S e 3X
Cu su lp h. 3X
Zn -glu c . 3X
K-a sp a r t . 3X
G u n a S . p . a .
9
3

D6
D3
S u i s -
O r g a n s
10 pg
NT3 NT4 Melatonin
H o r m o n e sN e u r o t r o p h in s
Plumbum
metallicum
Hepar
Lobo
frontalis
Glandula
suprarenalis
HypothalamusBaryta
carbonica
H o m e o p a t h i c
R e m e d i e s
Phenilalanine
Thyrosine
Oxitocine
TRH
LH-RH
ACTH Acidum
DL-malicum
Catalysts
Acidum
pyruvicum
H o r m o n e s
BDNF
Parabenzochinon
Baryum
oxalsuccinicum
Arnica
IGF-1
A minoacids

H e r b a l s
( A r n i c a
m o n t a n a )
H e r b a l s
( A r n i c a
m o n t a n a )
Ca t a l ys t
s a n d
a m i n o a
c i d s
Ca t a l ys t
s a n d
a m i n o a
c i d s
G r o w t h
f a c t o r s
G r o w t h
f a c t o r s
H o r m o n e sH o r m o n e s
Co u r t e s y fr o m D r . I
Bia n c h i

Bia n c h i

M e l a t o n i n
In s u l i n
G r o w i n
F a c t o r
A CT H
Bia n c h i

O x i t o c i n e T R H L H - R H
Bia n c h i

• Cir c u l a t i n g m e l a t o n i n
d e c r e a s e s w i t h a g e a n d in
r e c e n t ye a r s m u c h in t e r e s t
h a s b e e n f o c u s e d o n it s
im m u n o m o d u l a t o r y e f f e c t .
• M e l a t o n i n s t i m u l a t e s t h e
p r o d u c t i o n o f p r o g e n i t o r
c e l l s f o r g r a n u l o c yt e s -
m a c r o p h a g e s . It a l s o
s t i m u l a t e s t h e p r o d u c t i o n
o f N K c e l l s a n d CD 4+ c e l l s
a n d in h i b i t s CD 8+ c e l l s .
• T h e p r o d u c t i o n a n d r e l e a s e
o f v a r i o u s c yt o k i n e s f r o m
N K c e l l s a n d T - h e l p e r
lym p h o c yt e s a l s o a r e
e n h a n c e d b y m e l a t o n i n .
• M e l a t o n i n p r e s u m a b l y
r e g u l a t e s im m u n e f u n c t i o n
b y a c t i n g o n t h e im m u n e -
o p i o i d n e t w o r k , b y a f f e c t i n g
G p r o t e i n - c A M P s i g n a l
M e l a t o n i n h a s t h e
p o t e n t i a l
t h e r a p e u t i c v a l u e
t o e n h a n c e
im m u n e f u n c t i o n
in a g e d
in d i v i d u a l s a n d in
p a t i e n t s in a n
im m u n o c o m p r o m
Bia n c h i

 Insulin- like growth factors ( I G F s ) a r e
p o l i p e p t i d e s w i t h h i g h s e qu e n c e
s i m i l a r i t y t o in s u l i n
 IG F - 1 is m a i n l y s e c r e t e d b y t h e li v e r
a s a r e s u l t o f s t i m u l a t i o n b y G H .
 IG F - 1 is im p o r t a n t f o r b o t h t h e
r e g u l a t i o n o f n o r m a l p h ys i o l o g y, a s
w e l l a s a n u m b e r o f p a t h o l o g i c a l
s t a t e s , in c l u d i n g c a n c e r
 IG F a x i s h a s b e e n s h o w n t o p l a y
r o l e s in t h e p r o m o t i o n o f c e l l
p r o l i f e r a t i o n a n d in h i b i t i o n o f
a p o p t o s i s
 F a c t o r s t h a t a r e k n o w n t o c a u s e
v a r i a t i o n in t h e le v e l s IG F - 1 in t h e
c i r c u l a t i o n in c l u d e a n in d i v i d u a l s
Bia n c h i

 I t w a s d e m o n s t r a t e d t h a t
a d m i n i s t r a t i o n o f A CT H le d t o
f a c i l i t a t i o n o f le a r n i n g a n d
s t r e n g t h e n i n g o f m e m o r y
p r o c e s s e s ( c o n d i t i o n e d r e f l e x
t r a c e s ). A CT H p r o m o t e d
s t r e n g t h e n i n g o f m o v e m e n t ,
o r i e n t a t i o n a l - i n v e s t i g a t i v e ,
a n d in t e r s i g n a l a c t i v i t i e s ,
p r o d u c e d h yp e r a l g e s i a , a n d
b l o c k e d t h e e f f e c t s o f
n a l o x o n e
 A CT H is in v o l v e d in m o t i v a t i o n ,
Bia n c h i

 O x yt o c i n is a m a m m a l i a n h o r m o n e
t h a t a l s o a c t s a s a
n e u r o t r a n s m i t t e r in t h e b r a i n .
 O x yt o c i n is r e l e a s e d d u r i n g o r g a s m
in b o t h s e x e s .
 In t h e b r a i n , o x yt o c i n is in v o l v e d in
s o c i a l r e c o g n i t i o n a n d b o n d i n g ,
a n d m i g h t b e in v o l v e d in t h e
f o r m a t i o n o f t r u s t b e t w e e n p e o p l e ,
in g e n e r o s i t y a n d in t h e r e d u c t i o n
o f f e a r
 Ca n im p a i r m e m o r y r e t r i e v a l in
c e r t a i n a v e r s i v e m e m o r y t a s k s .
Bia n c h i

 T h e b r a i n t r i p e p t i d e
t h yr o t r o p i n - r e l e a s i n g
h o r m o n e ( T R H ) h a s b e e n
d e m o n s t r a t e d t o f a c i l i t a t e
c h o l i n e r g i c
n e u r o t r a n s m i s s i o n .
 T R H m a r k e d l y a t t e n u a t e d
s c o p o l a m i n e - i n d u c e d
im p a i r m e n t o f s o m e
m e a s u r e s o f m e m o r y,
m o s t n o t a b l y o n a
s e l e c t i v e r e m i n d i n g t a s k .
 Cognitive study suggest a facilitatory
role for T R H in human memory
processes.
 S cientific studies suggest that
stimulation of T R H may be useful for
Bia n c h i

 N e u r o t r o p h i c f a c t o r s
a r e e n d o g e n o u s
p r o t e i n s t h a t a l t e r t h e
s u r v i v a l , d e v e l o p m e n t ,
m a i n t e n a n c e , a n d
d i f f e r e n t i a t i o n o f
n e u r o n s .
 E v i d e n c e h a s
in d i c a t e d t h a t
n e u r o t r o p h i c f a c t o r s
m a y b e im p l i c a t e d in
t h e n o r m a l f u n c t i o n a l
a c t i v i t y o f n e r v e c e l l s .
 T h e s e m o l e c u l e s a r e
g e n e r a l l y s m a l l ,
s o l u b l e p r o t e i n s w i t h
Bia n c h i

 N erve G rowth F actor (N G F ) T h e
f i r s t k n o w n n e u r o t r o p h i n ,
a c t s p r e d o m i n a n t l y o n
s ym p a t h e t i c a n d s e n s o r y
n e u r o n s .
 Brain D erived N eurotrophic F actor
(BD N F ) S u p p o r t s
m o t o n e u r o n
d e v e l o p m e n t a n d
s u r v i v a l in a n i m a l s a n d
p r e v e n t s n a t u r a l l y
o c c u r r i n g d e a t h
 N eurotrophin 3 (N T - 3) N T - 3 is
r e l a t e d t o N G F a n d h a s
h o m o l o g y w i t h it . It is
f o u n d in m o t o r n e u r o n s ,
s ym p a t h e t i c n e u r o n s a n d
s o m e p e r i p h e r a l s e n s o r y
Bia n c h i

• A c t i n g o n c e r t a i n CN S n e u r o n s
a n d o n t h e p e r i p h e r a l n e r v o u s
s ys t e m
• H e l p s t o s u p p o r t t h e s u r v i v a l o f
e x i s t i n g n e u r o n s a n d e n c o u r a g e
t h e g r o w t h a n d d i f f e r e n t i a t i o n o f
n e w n e u r o n s a n d s yn a p s e s
• A c t i v e in t h e H yp p o c a m p u s ,
Co r t e x , Ba s a l F o r e b r a i n a r e a s v i t a l
t o le a r n i n g , m e m o r y, a n d h i g h e r
t h i n k i n g .
• A l t h o u g h t h e v a s t m a jo r i t y o f
n e u r o n s in t h e b r a i n a r e f o r m e d
p r e n a t a l l y, p a r t s o f t h e a d u l t
b r a i n r e t a i n t h e a b i l i t y t o g r o w
n e w n e u r o n s f r o m n e u r a l s t e m
Bia n c h i

 BD N F is o n e o f t h e m o s t a c t i v e
n e u r o t r o p h i n s . M i c e b o r n
w i t h o u t t h e a b i l i t y t o m a k e BD N F
s u f f e r d e v e l o p m e n t a l d e f e c t s in
t h e b r a i n a n d s e n s o r y n e r v o u s
s ys t e m , a n d u s u a l l y d i e s o o n a f t e r
b i r t h , s u g g e s t i n g t h a t BD N F p l a ys
a n im p o r t a n t r o l e in n o r m a l
n e u r a l d e v e l o p m e n t
 BD N F is a c t u a l l y f o u n d n o t o n l y in
t h e b r a i n b u t a l s o in a r a n g e o f
t i s s u e a n d c e l l t yp e s : R e t i n a ,
M o t o r n e u r o n s , Kid n e ys a n d
P r o s t a t e .
 V a r i o u s s t u d i e s h a v e s h o w n
p o s s i b l e li n k s b e t w e e n lo w le v e l s
o f BD N F a n d c o n d i t i o n s s u c h a s :
D e p r e s s i o n , S c h i zo f r e n i a ,
Bia n c h i

 N eurotrophin- 3 (N T - 3) s u p p o r t s
t h e s u r v i v a l a n d
d i f f e r e n t i a t i o n o f n e u r o n e s in
t h e c e n t r a l a n d p e r i p h e r a l
n e r v o u s s ys t e m s t h r o u g h a
n u m b e r o f m e c h a n i s m s t h a t
o c c u r in a m a t t e r o f h o u r s o r
d a ys . N T - 3 m a y a l s o h a v e a
m o r e r a p i d m o d e o f a c t i o n
t h a t in f l u e n c e s s yn a p t i c
a c t i v i t y in m a t u r e n e u r o n e s .
N T - 3 , h a v e b e e n im p l i c a t e d in
t h e r e g u l a t i o n o f s yn a p t i c
t r a n s m i s s i o n a n d p l a s t i c i t y.
Bia n c h i

 In c r e a s i n g a m o u n t s o f e v i d e n c e in d i c a t e
t h a t in f l a m m a t o r y p r o c e s s e s a r e in v o l v e d
in t h e n e u r o t o x i c i t y o f A D . A c e n t r a l e v e n t
in t h e s e p r o c e s s e s a p p e a r s t o b e t h e
a c t i v a t i o n o f m i c r o g l i a b y a v a r i e t y o f
f a c t o r s , in c l u d i n g b a m yl o i d a n d
p r o i n f l a m m a t o r y c yt o k i n e s .
 A c t i v a t e d m i c r o g l i a in t u r n r e l e a s e
p r o i n f l a m m a t o r y c yt o k i n e s , s u c h a s IL - 1 - b,
IL - 6 , a n d T N F - a, t h a t m a y le a d t o n e u r o n a l
d e a t h a n d d ys f u n c t i o n b y a v a r i e t y o f
m e c h a n i s m s , in c l u d i n g
◦ e n h a n c e m e n t o f g l u t a m a t e - i n d u c e d
e x c i t o t o x i c i t y[
◦ in h i b i t i o n o f lo n g - t e r m p o t e n t i a t i o n ,
w h i c h li m i t s f u n c t i o n a l p l a s t i c i t y a f t e r
n e u r o n a l in ju r y[
Bia n c h i

D E M E N T I A
A l zh e i m e r ’s
D i s e a s e s
U p r e g u l a t e d .:
IL - 6
IL - 1 0
T N F 
D o w n r e g u l a t e d
.:
IL - 2
V a s c u l a r
D e m e n t i a
U p r e g u l a t e d .:
IL - 6
IL - 1 0
IL - 1 b
D o w n r e g u l a t e d
.:
IL - 2
Bia n c h i

T h yr o x i n e F e n i l a l a n i l n e
Bia n c h i

 N o n e s s e n t i a l a m i n o a c i d s yn t h e s i ze d in t h e b o d y
f r o m p h e n yl a l a n i n e . A s a b u i l d i n g b l o c k f o r s e v e r a l
im p o r t a n t b r a i n c h e m i c a l s , tyr o s i n e is n e e d e d t o
m a k e e p i n e p h r i n e , n o r e p i n e p h r i n e , s e r o t o n i n , a n d
d o p a m i n e , a l l o f w h i c h w o r k t o r e g u l a t e m o o d .
 D e f i c i e n c i e s in t h i s a m i n o a c i d is a s s o c i a t e d w i t h
d e p r e s s i o n .
 T yr o s i n e a l s o a i d s in t h e p r o d u c t i o n o f m e l a n i n a n d
in t h e f u n c t i o n o f t h e a d r e n a l , t h yr o i d , a n d p i t u i t a r y
g l a n d s . T yr o s i n e is a l s o in v o l v e d in t h e s yn t h e s i s o f
e n k e p h a l i n s , s u b s t a n c e s t h a t h a v e p a i n - r e l i e v i n g
e f f e c t s in t h e b o d y.
 L o w le v e l s o f tyr o s i n e h a v e b e e n a s s o c i a t e d w i t h lo w
b l o o d p r e s s u r e , lo w b o d y t e m p e r a t u r e , a n d a n u n d e r
a c t i v e t h yr o i d .
Be c a u s e tyr o s i n e b i n d s u n s t a b l e m o l e c u l e s (c a l l e d
Bia n c h i

H e p a r s u i s
• S u p p o r t o f D i g e s t i v e a n d D e t o x i c a t o r y
F u n c t i o n s
S u p r a r e n a l s u i s
• O p p o s i n g A g e a n d S t r e s s R e l a t e d
E n d o c r i n e d i s f u n c t i o n s
H yp o t h a l a m u s s u i s
• R e s e t t i n g o f b i o l o g i c a l c l o c k
L o b u s f r o n t a l i s s u i s
• A n t a g o n i zi n g Co g n i t i v e d e t e r i o r a t i o n
Bia n c h i

A p p l i c a t i o n o f
c yt o k i n e s m o d e l
i n A u t o i m m u n e
D i s e a s e s a n d
M u s c l e - S k e l e t i c a l
P a i n M a n a g e m e n t
A p p l i c a t i o n o f
a n t a g o n o s t i c
l o w d o s e S KA -
a c t i v e t e d
c yt o k i n e s m o d e l
i n A u t o i m m u n e
D i s e a s e s a n d
M u s c l e - S k e l e t i c a l
P a i n M a n a g e m e n t© D i p a r t i m e n t o

1 1 6
1 1 6
I nflammation
Cytokines
I N F L A M M A T I O N
A N T I - I nflammation
Cytokines
I L - 1
T N F - α
6
• I L - 1
• T N F - α
• I L - 6
A nti- I L -
1 0
• A nti- I L -
• I L - 4
• I L - 1 0

Interleukin 1 (IL - 1 ) cytokine
secreted by macrophages,
monocytes, dendritic cells,
fibroblasts and endothelial
cells
• I L - 1 support inflammatory
processes
• Stimulates prostaglandins
production © D i p a r t i m e n t o
INTERLEUKINE-1 (α; ß)

I L - 1
IN F L A M M A T I O NS YN O VI A L
P A N N U S
F O R M A T I O N
CA R T I L A G E
BR E A KD O WN S
BO N E
R E S O R P T I O N

IL-1 (α; ß) ACTION MECHANISM
I L - 1 ( α; ß) a c t i v a t e :
1 . cyclooxygenase type 2
(CO X2)
2.prostaglandin E 2 (P G E 2)
3.nitric oxide (N O )

CONVENTIONAL DRUGS TO STOP
INTERLEUKINE-1 EFFECTS
N S A I
D s
CO R T
I S O N
A S A
- - -
CO X2 P G E 2 N O

Low dose SKA-actived Antibody Anti
Interleukins -1 (α and β) in Pain
Management
A nti
I L - 1
I L
-
1
CO X
2
P G
E 2
N O
-
BL O C
K
A nti
I n t e r l e u k i n s - 1
( α; ß) act a s
N S A I D s (A ),
cortisone (B) and, in
part, as salicylates (C),
w i t h o u t t h e
n e g a t i v e s i d e
e f f e c t s c a u s e d

T HE R A P E U T I C A P P R O A CH WIT H
L O W D O S E S .K.A . A N T I BO D Y
A N T I IL - 1 , IL - 4 & I L - 1 0 IN
M U S CL E - S KE L E T A L P A I N
M A N A G E M E N T
• A nti I L - 1 4CH  D ecrease of
acute inflammation.
• I L - 1 0 4CH  D ecrease of chronic
inflammation.
• I L - 4 4CH  Control of autoimmune© D i p a r t i m e n t o

• Cytokines are effective
• However pharmacological doses
is plagued with severe adverse
effects
U nless…
1. Marinaro, M. et al. 1999. Use of intransal IL-12 to target predominantly
Th1 responses to nasal and Th2 resposnses to oral vaccines given with
cholera toxin. J. Immunol. 162(1): 114-121
2. Mariinaro, M. et al. 1997. Oral but not parenteral interleukin IL-12
redirects T helper 2 (Th2)-type resposnses to an orola vaccine without
altering mucosal IgA responses. J. Exp. Med. 185(3): 415-427
3. Lee, S. Y. et al. 2001. Oral administration of IL-12 suppresses
anaphylatctic reactions in a murine model of peanut hypersensitivity. Clin.
Immunol. 101(2): 220-228

END ORPHIN
En do r p hin s a r e o r g a n i c c he mi c a l
s ubs t a n c e s p r o duc e d by t he CNS,
ha vin g a n t ip a in a n d p hys io lo g ic a l
c ha r a c t e r i s t ic s s imila r t o t ho s e o f
morphine a n d opium – ho we ve r t he y
ha ve a wide r r a n g e
En do r p hin s , like a n umbe r o f
mo r p hi n ic o r ig i n a lka lo ids , c a n
c a us e s t a t e s o f e up ho r ia a n d
s o mn o le n c e a c c o r din g t o t he
qua n t i t y r e l e a s e d

PRM: What is derived from Homeopathy?
The study of the pharmacological effects of homeopathized
PLANT, MINERALS and ANIMAL COMPONENTS on
healthy humans and their usage depending on the principles
of similarity and effect inversion
in an ill subject.
G u n a S . p . a .
1 25

• Ac o n i t i n 10-5 M 
Fi br i lla t i o n
• Ac o n i t i n 10-7 M 
Br a dyc a r di a
• Ac o n i t i n 10-18 M  No e ffe c t
o n he a l t hy
he a r t
 Ryt hm
A conitin experimentation
Pennec, J.P., Aubin, M (1984) – Effect of Aconitum and Veratrum on
the isolated and perfused heart of the common eel. Comp. Biochem,
Physiol. 776:367.
Diffe r e n t e ffe c t s o f Ac o n i t i n c o n c e n t r a t i o n s
o n is o la t e d a n d p e r fus e d e e l he a r t :
X5
X7
X1 8
G u n a S . p . a .

0
5000
10000
15000
20000
25000
35
S-cpm/100gSMPS
Co n t r o l
5 mg c o r t is o n e
0.5 mg c o r t is o n e
0.0005 mg c o r t i s o n e
0.00005 mg c o r t is o n e
0.000005 mg c o r t is o n e
H a us s Exp e r ime n t a t i o n (1968)
S T U D I E S O N T HE "N O N S P E CI F I C M E S E N CHYM A L R E A CT I O N " A N D T HE “1
T R A N S I T ZO N E " IN M YO CA R D I A L L E S I O N S A N D A T HE R O S CL E R O S I S
W. H . H a u s s , U . G e r l a c h , G . Ju n g e - H ül s i n g , H . T h e m a n n W. Wir t h
A n n a l s o f th e N e w Y o r k A c a d e m y o f S c i e n c e s , V o l u m e 1 56 , E x p e r i m e n t a l
"M e t a b o l i c " Ca r d i o p a t h e s a n d th e i r R e l a t i o n s h i p t o H i m a H e a r t D i s e a s e ,
P a g e 20 7- 21 8, Ja n 1 96 9, d o i : 1 0 . 1 1 1 1 / j. 1 749- 6 6 3 2. 1 96 9. t b 1 6 729. x
Effe c t s o f va r yin g g luc o c o r t ic o id c o n c e n t r a t i o n s o n
me s e n c hyma l s ys t e m tur n -o ve r
(c o n n e c t ive ti s s ue bio l o g i c a l a c t i vit y)
G u n a S . p . a .

High dose
S t r yc n
o s
N u x
v o m i c
a
+ + +
+
Increased excitability of
parasympathetic fibers
p a r a s ym p a t h
e t i c f i b e r
a c e t yl c h o l i n
e
A c e t yl c h o l i n e
r e c e p t o r
P a r i e t a l c e l l
o f g a s t r i c
m u c o s a
p r o t
o n
p o m
p
+
H Cl
( h yd r o c h l o r i
c a c i d )
+
E ffects of high dose S trycnos N ux vomica on acetylcholine
receptors of
gastric mucosa parietal cells
G u n a S . p . a .

Homeopathic
dose
S t r yc n o
s N u x
v o m i c a
- - -
-
p r o t
o n
p o m
p
-
-
E ffects of ho meo pa t hic do s e S trycnos N ux vomica on
acetylcholine receptors of gastric mucosa parietal cells
D ecreased excitability of
parasympathetic fiber
p a r a s ym p a t h
e t i c f i b e r
A c e t yl c h o l i
n e
A c e t yl c h o l i n e
r e c e p t o r
P a r i e t a l c e l l
o f g a s t r i c
m u c o s a
H Cl
( h yd r o c h l o r i
c a c i d )
G u n a S . p . a .

• A R N I CA (Arnica
montana)
• A CO N I T U M (Aconitum
napellus)
• R HU S T O X. (Rhus
toxicodendron)
• CIM I CI F U G A (Cimicifuga
racemosa)
• VIO L A O D O R A T A
• CA U L O P HYL L U M
(Caulophyllum talictroides)
• A CI D U M BE N ZO I CU M
• L E D U M (Ledum palustre)
• CO L O CYN T HI S (Citrullus
colocynthis)
I mportant homeopatic single
remedies for P ain M anagement:
• A CI D U M F O R M I CI CU M
• G N A P HA L I U M
P O L YCE P HA L U M
• R HO D O D E N D R O N
CHR YS A N T HU M
• L A CHE S I S M U T U S
• BR YO N I A A L BA
• HYP E R I CU M
P E R F O R A T U M
• BE L L A D O N N A (Atropa
belladonna)
• CR O T A L U S HO R R I D U S
• KA L M I A L A T I F O L I A
• E T C.

• RES (r e t i c u lo e n do t he l
ia l syste m )
st i m u la t i o n a n d
in hi bi t i o n o f the
p r o c e ss.
Ho m e o p a t hi c a n d
Mo le c o la r Bio lo gy
r e m e di e s… in 1 dr u g
G UNA-FLAM
G u n a S . p . a .
Ac o n i t u m *
Be lla do n n a *
Ap i s*
Br yo n i a *
Pyr o ge n i u m *
Phyt o la c c a *
TG F 1 be t a ***
IL 10***
n e u r o ge n i c ,
va sc u la r e xu da t i ve
p ha se s o f t he
p r o c e ss*.
• In hi bi t i o n o f t he
c a sc a de st a r t i n g
p o i n t **.
im m u n o lo gi c a n t i -
a c t i vi t y ha vi n g Th2-Th3
p o la r i t y***.
Ac o n i t u m *
Pyr o ge n i u m
Me la t o n i n 4C
Co n ju n c t i va t i ssu e 12X
ECM (e xt r a c e llu la r
m a t r i x)
f u n c t i o n t hr o u gh
hyp o p hyse a l
ho r m o n e a c t i o n
a n d p i n e a l gla n d
st i m u la t i o n

S U P P O R T I VE O R A L
T HE R A P Y I N
P A I N
M A N A G E M E N T
Directions• G U N A - F L A M : 20 d r o p s
t w i c e a d a y f o r a t
l e a s t 1
m o n t h

MATRIX
MEMBRANE
RECEPTORS
VESSELS
THECONNECTIVETISSUE
Morpho-functionalunity:vessel-
matrix-membranereceptor
G u n a S . p . a .

Ma t r i x
liqu i f i c a t i
o n a n d
dr a i n a ge
Ac t i o n
a ga i n st t o xi n
im p r e gn a t i o
n
Lym p ha t i
c
dr a i n a ge
e n e r gy
•Ma t r i x
(p r o m o t i n g
e n e r gy
•Ma t r i x
(p r o m o t i n g
•Ac. D-L malicum 6X*
•Natrium oxal. 6X*
•Natrium pyruv. 6X*
•NADID 6X*
•Trychinoil 6X*
•Vit. C 2X*
•Ac. L(+) lacticum3X**
(thr o u gh
t o xi n s*.
(thr o u gh
t o xi n s*.
•Pyrogenium 12X*
•Fucus 3X*
•Tyrosine 2X**
•Histidine 2X**
f o r dr a i n a ge
f o r dr a i n a ge
•Lymphatic vessel 6X
t e n de n c y t o
(psychcosis).**
•Ma t r i x
t e n de n c y t o
(psychcosis).**
•Ma t r i x
•Hyaluronidase 6X*
•Thuja 6/8/12/30/200X**
•Natrium sulfuricum 6/8/12/30/200X **
•Prolactine 6X***
•DHEA 6X***
Fu n da m e n t a l
in c r e a se d
r a t e . *
Fu n da m e n t a l
in c r e a se d
r a t e . *
•IL 6 4C*
•DHEA 6X*
•Pyrogenium 12X*
•Conjunctive Tissue 6X*
•Tyrosine 2X**
•Histidine 2X**
•Prolactine 6X***
G UNA-
MATRIX
G u n a S . p . a .
1 3 4

Lym p h f lo w wit h
st a bi li za t i o n o f
ve sse l wa ll t o n e
wit h c o n se qu e n t
r e du c t i o n o f t he
e xu da t e a n d t he
lym p ho e de m a .
Lym p h f lo w wit h
st a bi li za t i o n o f
ve sse l wa ll t o n e
wit h c o n se qu e n t
r e du c t i o n o f t he
e xu da t e a n d t he
lym p ho e de m a .
•In hi bi t i o n o f t he
p r o li f e r a t i ve
t e n de n c i e s o f
t he lym p ho -
e p i t he li a l t i ssu e s
•In hi bi t i o n o f t he
p r o li f e r a t i ve
t e n de n c i e s o f
t he lym p ho -
e p i t he li a l t i ssu e s
•S t i m u la t i o n
o f Hu m o r a l
Im m u n i t y a n d
in hi bi t o r y
t he e xc e ssi ve
c e ll m e di a t e d
c o m p e n sa t o r y
r e sp o n se
•S t i m u la t i o n
o f Hu m o r a l
Im m u n i t y a n d
in hi bi t o r y
t he e xc e ssi ve
c e ll m e di a t e d
c o m p e n sa t o r y
r e sp o n se
•Re du c t i o n o f
lo c a l
in f la m m a t i o n o n
lym p ho -e p i t he li a l
t i ssu e s.
• Re du c t i o n o f
lym p ha t i c sp a sm
du e t o
wit h r e st o r a t i o n
o f t he lym p ha t i c
c i r c u la t i o n .
•Re du c t i o n o f
lo c a l
in f la m m a t i o n o n
lym p ho -e p i t he li a l
t i ssu e s.
• Re du c t i o n o f
lym p ha t i c sp a sm
du e t o
wit h r e st o r a t i o n
o f t he lym p ha t i c
c i r c u la t i o n .
G UNA-LYMPHO
REACTIVATION OF THE
LYMPHATIC
CIRCULATION
HYPERTROPHY
AND HYPERPLAS IA
OF THE LYMPHATIC
ORG ANS
S TRENG HTENING
IMMUNE D EFENCE
ANTI-INFLAMMATORY
ACTIVITY ON THE
LYMPHO-EPITHELIAL
TIS S UES
G u n a S . p . a .
Hydr a st i s 1X
Ju gla n s 3X
G r a p hi t e s 6/12/30/200X
Ma gn e si u m
p ho sp ho r i c u
m
6/12/30/200X
Ju gla n s
Ma gn e si u m
p ho sp ho r i c u
m
6/12/30/200X
Ju gla n s
Ca le n du la 1X
Phyt o la c c a 3X
Ap i s 8X
Ma gn e si a p ho sp h.
6/12/30/200X
Myo so t i s 3X
Equ i se t u m 3X
Hydr o c o t i le 1X
Ta r a xa c u m 1X
S a r sa p a r i lla 3X
Lym p ha t i c ve sse l 6X
Ca p i lla r y t i sssu e 6X
L-Thyr o xi n 6/12X
Ve i n p o r c i n e 6X
D -L Ma li c Ac . /Fu m a r i c u m Ac . /Pyr u vi c u m Ac .
Tryc hi n o il/Na t r i u m o xa la c .
1 3 5

D R A I N A G E T HE R A P Y I N
P A I N M A N A G E M E N T
Directions
• G U N A - M A T R I X: 20
d r o p s t w i c e a d a y f o r a t
l e a s t 2
m o n t h s
• G U N A - L YM P HO : 20
l e a s t 2 m o n t h s
A L L T H E A . M . P R O D U CT S CA N BE
T A KE N T O G E T H E R ( f o r e x a m p l e
p u t t i n g 3 0 - 40 d r o p s o f e a c h
m e d i c i n e in 1 li t r e b o t t l e o f w a t e r .
T h e p a t i e n t d r i n k s t h i s b o t t l e d u r i n g
t h e w h o l e d a y)

1 3 7
PAIN MANAGEMENT
- LOCAL TH ERAPY -

P .R .M . in
P ain
M anagement
Give relief to patients
in a NATURAL and
BIOLOGICAL WAY and
WITHOUT SIDE
EFFECTS.

G U N A- P O L Y A R T H R I T I S
Jo i n tp a i n
G U N A-M U S CL E
M u s c l ep a i n
G U N A-N E CK
G U N A-S H O U L D E R
G U N A-N E U R A L
N e r v ep a i n
G U N A-H I P
G U N A-T H O R A CI C
G U N A-L U M BA R
G U N A-IS CH I A L
G U N A-H A N D FO O T
Chart of area/zoneconnections

E very ampoule
contains 1 0 active
ingredients; 7 of
them are specific
for a specific type
of pain or parts of
the body; 3 of
them are specific
for pain © D i p a r t i m e n t o
T HE R A P E U T I C
U N I T

1 42
1 42
I nflammation
I nterleukine
I N F L A M M A T I O N
A N T I - I nflammation
A ntibody
I L - 1• I L - 1 A nti-
I L - 1
• A nti-
I L - 1

Interleukin 1 (IL - 1 ) cytokine
secreted by macrophages,
monocytes, dendritic cells,
fibroblasts and endothelial
cells.
I L - 1 S U P P O R T S
I N F L A M M A T O R Y
P R O CE S S E S
INTERLEUKINE-1 (α; ß)

IL-1 (α; ß) ACTION MECHANISM
I L - 1 ( α; ß) a c t i v a t e s :
1 . cyclooxygenase type 2
(CO X2)
2.prostaglandin E 2 (P G E 2)
3.prostaglandin D 2 (P G D 2)
4.nitric oxide (N O )

CONVENTIONAL DRUGS TO STOP
INTERLEUKINE-1 EFFECTS
N S A I
D s
CO R T
I S O N
A S A
- - -
CO X2 P G E 2/
D 2
N O

Low dose SKA-activated Antibody Anti
Interleukins -1 (α and β) in Pain
Management
A nti
I L - 1
I L
-
1
CO X
2
P G
E 2
N O
-
BL O C
K
A nti
I n t e r l e u k i n - 1
( α; ß) acts a s
N S A I D s , cortisone
and, in part, as
salicylate , w i t h o u t
t h e n e g a t i v e
s i d e e f f e c t s
c a u s e d b y

β-END ORPHIN
En do r p hin s a r e o r g a n i c c he mi c a l
s ubs t a n c e s p r o duc e d by t he CNS,
ha vin g a n t ip a in a n d p hys io lo g ic a l
c ha r a c t e r i s t ic s s imila r t o t ho s e o f
morphine a n d opium – ho we ve r t he y
ha ve a wide r r a n g e .
En do r p hin s , like a n umbe r o f
a lka lo ids , s uc h a s mo r p hin , c a n
c a us e s t a t e s o f e up ho r ia a n d
s le e p n e s s a c c o r din g t o t he
qua n t i t y r e l e a s e d.

H E A L T H
P HYS I O L O G I CA L
CO N CE N T R A T I O N
1 0
- 6
1 0-
1 5
4C – X6
Concentration of A nti I L - 1
(α; β) and β- endorphin

• A R N I CA (Arnica
montana)
• A CO N I T U M (Aconitum
napellus)
• R HU S T O X. (Rhus
toxicodendron)
• CIM I CI F U G A (Cimicifuga
racemosa)
• VIO L A O D O R A T A
• CA U L O P HYL L U M
(Caulophyllum talictroides)
• A CI D U M BE N ZO I CU M
• L E D U M (Ledum palustre)
• CO L O CYN T HI S (Citrullus
colocynthis)
I mportant homeopatic single
remedies in P .R .M . P ain
M anagement ampoules:
• A CI D U M F O R M I CI CU M
• G N A P HA L I U M
P O L YCE P HA L U M
• R HO D O D E N D R O N
CHR YS A N T HU M
• L A CHE S I S M U T U S
• BR YO N I A A L BA
• HYP E R I CU M
P E R F O R A T U M
• BE L L A D O N N A (Atropa
belladonna)
• CR O T A L U S HO R R I D U S
• KA L M I A L A T I F O L I A
• E T C.

1 52
• S t a n d a r d p r o t o c o l f o r i. m .
a d m i n i s t r a t i o n :
1 a m p o u l e 1 - 3 t i m e s a
w e e k a c c o r d i n g t o s e v e r i t y
a n d c l i n i c a l e v o l u t i o n .
• S t a n d a r d p r o t o c o l
a c c o r d i n g t o
m e s o t h e r a p e u t i c t e c h n i qu e :
1 - 2 a m p o u l e s p e r
t r e a t m e n t : 2 t r e a t m e n t s f o r
t h e f i r s t 2 w e e k s , t h e n 1
t r e a t m e n t a w e e k t i l l p a i n
r e l i e f ( a v e r a g e 8- 1 0
s e s s i o n s ).
Fo r c h r o n i c p a t h o l o g i e s :
c o n t i n u e 1 t r e a t m e n t a
P A I N
M A N A G E M E N T
T R E A T M E N T
P R O T O CO L

S U P P O R T I VE O R A L
T HE R A P Y I N
P A I N
M A N A G E M E N T
Directions• G U N A - F L A M : 20 d r o p s
t w i c e a d a y f o r a t
l e a s t 2
m o n t h s

• RES (r e t i c u lo e n do t he l
ia l syste m )
st i m u la t i o n a n d
in hi bi t i o n o f the
p r o c e ss.
Ho m e o p a t hi c a n d
Mo le c u la r Bio lo gy
r e m e di e s… in 1 sin gle
dr u g: G UNA-FLAM
G u n a S . p . a .
Ac o n i t u m *
Be lla do n n a *
Ap i s*
Br yo n i a *
Pyr o ge n i u m *
Phyt o la c c a *
TG F 1 be t a ***
IL 10***
n e u r o ge n i c ,
va sc u la r e xu da t i ve
p ha se s o f t he
p r o c e ss*.
• In hi bi t i o n o f t he
c a sc a de st a r t i n g
p o i n t **.
im m u n o lo gi c a n t i -
a c t i vi t y ha vi n g Th2-Th3
p o la r i t y***.
Ac o n i t u m *
Pyr o ge n i u m
Me la t o n i n 4C
Co n ju n c t i va t i ssu e 12X
ECM (e xt r a c e llu la r
m a t r i x)
f u n c t i o n t hr o u gh
hyp o p hyse a l
ho r m o n e a c t i o n
a n d p i n e a l gla n d
st i m u la t i o n

D R A I N A G E T HE R A P Y I N
P A I N M A N A G E M E N T
Directions
• G U N A - M A T R I X: 20
le a s t 2
m o n t h s
+
• G U N A - L YM P HO : 20
le a s t 2
m o n t h s
A L L T H E A . M . P R O D U CT S CA N BE
T A KE N T O G E T H E R ( f o r e x a m p l e
p u t t i n g 3 0 - 40 d r o p s o f e a c h
m e d i c i n e in 1 li t r e ( 3 3 f l o z) b o t t l e o f
w a t e r . T h e p a t i e n t d r i n k s t h i s
“t h e r a p e u t i c c o c k t a i l ” d u r i n g t h e
w h o l e d a y). © D i p a r t i m e n t o

G u n a S . p . a .
1 56
• WHE R E : intradermal
• HO W M A N Y P O I N T S : 5- 6- 7
• HO W M U CH: 0.3- 0.5 ml each
injection

S YR I N G E S F O R
P A I N
M A N A G E M E N T
2,5
ml
5 ml 1 0
ml
20
ml
IN S U
L I N

1 3
m m
.
N E E D L E S F O R P A I N
M A N A G E M E N T
30
G
L E N G HT
G A U G E

1 59
• Pa i n
s ymp t o ma t o lo g y
r e duc t i o n by me a n s
o f UP-REGULATION o f b–
En do r p hin
r e c e p t o r s
• Pa i n
En do r p hin
r e c e p t o r s
• Mo dul a t io n o f IL1
a a n d IL1 b p r o -
in fl a mma t o r y
a c t ivit y in the
tr i g g e r p ha s e o f
in fl a mma t io n
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
• Re duc t io n o f
de g e n e r a t ive
a r t i c ula r p a in o n a
c hr o n i c -e vo lut ive
ba s is
ba s is
p o lya r t i c ula r p a in
s ymp t o ma t o lo g y in
a c ut e in fla mma t io n
ha vin g diffe r e n t
lo c a liza t io n
lo c a liza t io n
•Be t a -En do r p hi n 4C
•An t i in t e r le u ki n 1 a lp ha 4C
•An t i in t e r le u ki n 1 be t a 4C
•Le dum p a lus t r e 8X
•Vis c um a lbum 10X
P.N. E. I.
a n t a lgi c
c o r e
An t i -
i n f la m m
a t o r y
c o r e
Chr o n i c
in f la m m a t o
r y p a i n
Ac u t e
in f la m m
a t o r y
p a i n
•Sa l yc i l ic um a c idum 2X
•Ac o n i t um 6X
•Dro s e r a 8X
•Co l c hi c um a ut umn a l e 10X
•Gua i a c um 10X
Exa m p le o f P.R. M. Pa i n Ma n a ge m e n t
a m p o u le :
GUNA®-POLYARTH RITIS
© Dip a r t ime n t o Sc i e n t ific o Gun a S.p .a .

1 6 0
Clin i c a l
In dic a t io n s
GUNA®-NECK
Ne c k p a i n due t o c a r t i l a g e
de g e n e r a t ive c e r vi c a l s p i n e
dis o r de r s (c e r vi c a l o s t e o a r t hr o s i s )
 Ne c k p a i n due t o c e r vi c a l mus c ul a r
t r i g g e r p o i n t s
 St iff n e c k s yn dr o me
 Simp le n e c k p a i n
 Whip l a s h
 Po s t ur a l n e c k a c he
 Me c ha n i c a l imba l a n c e (fa c e t jo i n t
s yn dr o me )
 Ce r vi c a l s p i n a l li g a me n t s yn dr o me
 Ce r vi c a l s p i n a l n e r ve r o o t p a in© Dip a r t ime n t o Sc i e n t ific o Gun a S.p .a .

1 6 1
• Riduzio n e de l l a
s i n t o ma t o lo g i a a lg ic a
p e r UP-REGULATION de i
r e c e t t o r i de ll a b–
En do r fin a
En do r fin a
• Mo dula t i o n o f IL1 a a n d
IL1 b p r o -in fl a mma t o r y
a c t ivi t y in the tr i g g e r
p ha s e o f in fl a mma t io n
• Mo dula t i o n o f IL1 a a n d
IL1 b p r o -in fl a mma t o r y
a c t ivi t y in the tr i g g e r
p ha s e o f in fl a mma t io n
Re duc t i o n o f c e r vi c a l
ra c hi s p a in
s ymp t o ma t o lo g y o f
diffe r e n t o r i g in :
• Fibr o mya lg ic o r ig in
(Picricum acidum)
• Sp a s t ic a n d/o r
c o n g e s t ive o r i g i n
(Crotalus horr., Nux vomica,
Magnesia phosph.)
• Ne vr a lg ic o r ig in
(Magnesia phosph.)
An a e s t he t i c o r i g i n :
• Picricum acidum
Re duc t i o n o f c e r vi c a l
ra c hi s p a in
diffe r e n t o r i g in :
• Fibr o mya lg ic o r ig in
(Picricum acidum)
• Sp a s t ic a n d/o r
c o n g e s t ive o r i g i n
(Crotalus horr., Nux vomica,
Magnesia phosph.)
• Ne vr a lg ic o r ig in
(Magnesia phosph.)
An a e s t he t i c o r i g i n :
• Picricum acidum
• Bio s t imul a t io n
c a r t i la g e ma t r ix
c o mp o n e n t s s yn t he s i s
(Cartilago)
• An t i-de g e n e r a t ive
a c t i o n (Discus intervertebralis)
• Bio s t imul a t io n
c a r t i la g e ma t r ix
(Cartilago)
• An t i-de g e n e r a t ive
a c t i o n (Discus intervertebralis)
• Be t a -En do r p hi n 4C
• An t i in t e r l e ukin 1 a l p ha 4C
• An t i in t e r le uki n 1 be t a 4C
• Ma g n e s i a p ho s p ho r ic a 12X
•Pic r i c um a c . 8X
• Cro t a l us ho r r idus 10X
• Nux vo mi c a 10X
• Sil i c e a 4X
• Stimul a t i o n o f
o s t e o bla s t s fun c t io n
a n d c o r r e c t io n o f
a r t i c ula r s t r uc t ur e
p a t ho lo g ie s
• Stimul a t i o n o f
o s t e o bla s t s fun c t io n
a n d c o r r e c t io n o f
a r t i c ula r s t r uc t ur e
p a t ho lo g ie s
• Ca r t i l a g o s ui s 4X
•In t e r ve r t e br a l dis k, Po r c i n e 4X
An t i-
de g e n e r a t i
ve c o r e 2
GUNA®-NECK
• Pa i n s ymp t o ma t o lo g y
r e duc t i o n by me a n s o f UP-
REGULATION o f b–
En do r p hi n re c e p t o r s
REGULATION o f b–
En do r p hi n re c e p t o r s P.N.E.I.
a n t a l g i c
c o r e
H o me o p a t h
ic a n t a l g i c
c o r e
An t i-
in fl a mma t o
ry c o r e
An t i-
de g e n e r a
ti ve c o r e
1

1 6 2
in t o s p e c ific a n d
s e le c t e d
lo c a l Ac up un c t ur e Po in t s
GUNA®-NECK
GV 16
GB 20
BL 10
GV 15
GB 21
GV 14
SI 9
SI 10
GB 21

1 6 3
in t o Tr ig g e r Po in t s a n d
r e fe r r e d p a in zo n e s
GUNA®-NECK
BL 10
BL 11
TP = Ma i n Tr i g g e r Po in t s a n d c o r r e l a t e d
Ac up un c t ur e p o i n t s
TP
TP
SI 15
TP/SI 14
C 7
C 7

1 6 4
GUNA®-TH ORACIC
Clin i c a l
In dic a t io n s
Tho r a c i c p a i n due t o c a r t i l a g e
de g e n e r a t ive t ho r a c i c s p in e
dis o r de r s (t ho r a c i c o s t e o a r t hr o s i s )
 Tho r a c i c p a in due t o s c o l i o s i s
 Tho r a c i c p a in due t o tho r a c ic
lo n g mus c l e t r i g g e r p o i n t s
 Pa i n due t o t ho r a c ic s p i n e
o s t e o p hyt o s is
 Simp le p o s t e r i o r t ho r a c i c p a i n
(tho r a c ic p a i n s yn dr o me )
 Me c ha n i c a l imba l a n c e (c o s t o -
ve r t e br a l fa c e t jo i n t s yn dr o me )
 Tho r a c i c s p i n a l li g a me n t
s yn dr o me
 Tho r a c i c s p i n a l n e r ve r o o t p a in
 Pa i n fr o m s p in a l o s t e o p o r o s i s

1 6 5
En do r fin a
En do r fin a
Re duc t i o n o f the
do r s a l ra c his p a in
diffe r e n t o r i g in , typ e
a n d lo c a liza t io n :
Ne ur o -mus c ul a r
o r ig in (Cimicifuga, Chininum
sulph., Conium)
•Sp a s t ic a n d/o r
c o n g e s t ive
o r ig in (Chelidonium,
Spongia)
LOCALIZATION
Do r s a l ra c hi s : dir e c t , a ll;
he p a t i c re fl e x, Chelidonium.
In t e r c o s t a l p a in : Spongia
Re duc t i o n o f the
do r s a l ra c his p a in
Ne ur o -mus c ul a r
o r ig in (Cimicifuga, Chininum
sulph., Conium)
•Sp a s t ic a n d/o r
c o n g e s t ive
o r ig in (Chelidonium,
Spongia)
LOCALIZATION
Do r s a l ra c hi s : dir e c t , a ll;
he p a t i c re fl e x, Chelidonium.
In t e r c o s t a l p a in : Spongia
•An t i -de g e n e r a t ive a n d
a n t i-n e ur a lg ic a c t io n
•An t i -de g e n e r a t ive a n d
a n t i-n e ur a lg ic a c t io n
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r le ukin 1 be t a 4C
•Che l i do n ium ma jus 4X
•Cimi c i fug a ra c e mo s a 4X
•Co n ium ma c ula t um 6X
•Chin i n um s ulp hur ic um 8X
•Sp o n g i a to s t a 10X
• Ca l c a r e a p ho s p ho r i c a 6X
•Co n s t i t ut io n a l
c o r r e c t io n o f a r t ic ul a r
s t r uc t ur e p a t ho lo g i e s
•Co n s t i t ut io n a l
s t r uc t ur e p a t ho lo g i e s
•In t e r ve r t e br a l dis k, Po r c i n e 4X
Co n s t i t ut i o n
a l c o r e
GUNA®-TH ORACIC
REGULATION o f b–
REGULATION o f b–
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
P.N.E.I.
a n t a l g i c
c o r e
H o me o p a t h
ic a n t a l g i c
c o r e
An t i-
in fl a mma t o
ry c o r e
An t i-
de g e n e r a
ti ve c o r e

1 6 6
GUNA®-LUMBAR
Clin i c a l
In dic a t io n s Lumba r p a in due t o c a r t i l a g e
de g e n e r a t ive lumba r s p in e dis o r de r s
(lumba r a n d lumba r -s a c r a l a r t hr o s i s )
 Lumba r ve r t e br a l o s t e o p hyt o s is
 Lo w ba c k p a i n due t o mus c ul a r a n d
t e n din o us t r ig g e r p o in t s
 Simp le lumba r p a i n (lo w ba c k
s yn dr o me )
 We a k lo w ba c k s yn dr o me
 Po s t ur a l lo w ba c k a c he
 Lumba r a n d lumba r -s a c r a l
me c ha n ic a l imba la n c e
 Lumba r a n d lumba r -s a c r a l s p i n a l
li g a me n t s yn dr o me
 Sa c r o -i li a c s yn dr o me
 Sp i n a l lumba r a n d lumba r -s a c r a l
n e r ve r o o t p a in

1 6 7
•Pa i n
o f UP-REGULATION o f
b–En do r p hi n
r e c e p t o r s
•Pa i n
o f UP-REGULATION o f
b–En do r p hi n
r e c e p t o r s
•Mo dula t io n o f IL1
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
•Mo dula t io n o f IL1
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n•An t i -de g e n e r a t ive
a n d a n t i -n e ur a lg ic
a c t i o n
•An t i -de g e n e r a t ive
a n d a n t i -n e ur a lg ic
a c t i o n
Re duc t i o n o f the lumba r
ra c hi s p a in
•Ne ur o -mus c ul a r o r i g i n
(Bryonia, Alumina, Ac.
Phosphoricum). Ar t ic ul a r
o r ig in (Natrium sulph.)
•Typ e – c r a mp -like p a in
(Ac. phosphoricum); mus c ula r
p a r e s i s p he n o me n a
(Alumina)
•Lo c a liza t io n –
Lumbo s a c r a l ra c his :
dir e c t , Hamamelis;
a bdo mi n a l r e fle x, Sepia
Re duc t i o n o f the lumba r
ra c hi s p a in
•Ne ur o -mus c ul a r o r i g i n
(Bryonia, Alumina, Ac.
Phosphoricum). Ar t ic ul a r
o r ig in (Natrium sulph.)
•Typ e – c r a mp -like p a in
(Ac. phosphoricum); mus c ula r
p a r e s i s p he n o me n a
(Alumina)
•Lo c a liza t io n –
Lumbo s a c r a l ra c his :
dir e c t , Hamamelis;
a bdo mi n a l r e fle x, Sepia
•Be t a -En do r p hin 4C
•An t i in t e r le uki n 1 a l p ha 4C
•An t i in t e r l e ukin 1 be t a 4C
In t e r ve r t e br a l dis k, Po r c i n e 4X
P.N.E.I.
An t a l g i c
c o r e
An t i -
in fl a mma t o
r y c o r e
An t i -
de g e n e r a t iv
e c o r e
H o me o p a t h
ic a n t a lg ic
c o r e
•Br yo n i a 4X
•Se p i a o ffi c i n a l i s 4X
•Pho s p ho r i c um a c . 6X
•H a ma me l i s vir g i n i a n a 6X
•Alumi n a 8X
•Na t r um s ul p hur i c um 8X
GUNA®-LUMBAR

1 6 8
GUNA®-ISCH IAL
Clin i c a l
In dic a t io n s
Sc ia t ic a p a in
Lumba r -s c ia t ic
p a i n
Ne r ve p a in in t he
lo we r lumba r s p in e
Le g n e r ve p a in
due t o p o s t -s ur g e r y
t r e a t me n t o f dis k
he r n i a t io n L4-L5, L5-
S1
Mo r t o n n e ur o ma © Dip a r t ime n t o Sc i e n t ific o Gun a S.p .a .

1 6 9
P.N.E.I.
a n t a l g i c
c o r e
An t i-
in fl a mma t o r
y c o r e
Prima r y
n e ur a l g i c
p a i n
Se c o n da r y
n e ur a l g i c
p a i n
REGULATION o f b–En do r p hin
r e c e p t o r s
REGULATION o f b–En do r p hin
r e c e p t o r s
• Mo dul a t io n o f IL1 a
a n d IL1 b p r o -
in fl a mma t o r y a c t ivit y
in the tr ig g e r p ha s e
o f in fla mma t io n
a n d IL1 b p r o -
Mo dula t io n o f s c ia t i c
p a in by me a n s o f
in fl a mma t io n
n e ur o g e n p ha s e
in hibit i o n (Aconitum and
Arsenicum) a n d dir e c t
a c t i o n o n the
s c ia t ic n e r ve
(Gnaphalium)
Mo dula t io n o f s c ia t i c
p a in by me a n s o f
in fl a mma t io n
n e ur o g e n p ha s e
in hibit i o n (Aconitum and
Arsenicum) a n d dir e c t
a c t i o n o n the
s c ia t ic n e r ve
(Gnaphalium)
• Pa i n mo dul a t io n by
me a n s o f a r e duc t io n
in the p r o g r e s s io n o f
o s t e o c ho n dr o s i s
(Cimicifuga), c o xo -fe mo r a l
a r t hr o s is (Rhus tox.),
ba c ka c he (Rhus tox).
me a n s o f a r e duc t io n
in the p r o g r e s s io n o f
o s t e o c ho n dr o s i s
(Cimicifuga), c o xo -fe mo r a l
a r t hr o s is (Rhus tox.),
ba c ka c he (Rhus tox).
• An t i in t e r le uki n 1 a l p ha 4C
• An t i in t e r le un i n 1 be t a 4C
•La c he s is mutus 8X
•Gn a p ha l ium p o l yc e p ha lum 4X
•Ars e n ic um a lbum 6X
•Rho do de n dr o n c hr ys a n t um 6X
•Ac o n i t um n a p e l lus 8X
• Cimi c ifug a 4X
• La c he s i s mutus 8X
• Mo dul a t io n o f
a bdo mi n a l wa l l r e fl e xe d
s c ia t ic p a in (Lachesis) a n d
il ia c -s a c r a l lumba r p a i n
(Cimicifuga)
• Mo dul a t io n o f
a bdo mi n a l wa l l r e fl e xe d
s c ia t ic p a in (Lachesis) a n d
il ia c -s a c r a l lumba r p a i n
(Cimicifuga)
•Cimi c ifug a 4X
•Rhus to xi c o de n dr o n 4X
Re fle xe d
n e ur a l g i c
p a i n
GUNA®-ISCH IAL

1 70
GUNA®-SH OULDER
Clin i c a l
In dic a t io n s
Sc a p ula r -hume r a l p e r i-a r t hr i t i s
Sho ulde r p a i n
 Sho ulde r -a r m s yn dr o me
Fr o ze n s ho ulde r
 Sho ulde r p a i n due t o dis lo c a t i o n ,
t he r a p e ut i c r e s t
 Ep ic o n dyl i t i s

1 71
• Pa i n
En do r p hin
r e c e p t o r s
• Pa i n
En do r p hin
r e c e p t o r s
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
• An t i-de g e n e r a t ive a n d
c hr o n i c a n t i -in fl a mma t o r y
a c t i o n (Tendon, Porcine)
• An t i-de g e n e r a t ive a n d
c hr o n i c a n t i -in fl a mma t o r y
a c t i o n (Tendon, Porcine)
Re duc t i o n o f s ho ulde r
p a in o f diffe r e n t
o r ig in a n d typ e :
• Ne ur a lg ic o r ig in
(Argentum nitricum, Ferrum
phosph., Iris)
• Mus c ula r o r ig in
(Ranunculus, Sanguinaria)
• Ac ut e p a i n (Ferrum, Iris)
• Chr o n ic p a in (Argentum
nitricum, Ranunculus)
Re duc t i o n o f s ho ulde r
p a in o f diffe r e n t
o r ig in a n d typ e :
• Ne ur a lg ic o r ig in
(Argentum nitricum, Ferrum
phosph., Iris)
• Mus c ula r o r ig in
(Ranunculus, Sanguinaria)
• Ac ut e p a i n (Ferrum, Iris)
• Chr o n ic p a in (Argentum
nitricum, Ranunculus)
•Ca r t i l a g o s ui s 4X
•Te n do n , Po r c i n e 6X
P.N.E.I.
a n t a lg ic
c o r e
An t i -
in fl a mma t o
r y c o r e
An t i -
de g e n e r a
tive c o r e
H o me o p a
thic
a n t a lg ic
c o r e
•Arg e n t um n i t r i c um 8X
•Fe r r um p ho s p ho r i c um 8X
•Iris ve r s i c o l o r 8X
•Sa n g ui n a r i a c a n a de n s i s 8X
• Ra n un c ulus bulbo s us 10X
GUNA®-SH OULDER

1 72
GUNA®-H ANDFOOT
Clin i c a l
In dic a t io n sOs t e o a r t hr i t i s o f dig i t s
p a i n
Rhizo a r t hr o s i s o f t he
t humb (Fo r e s t i e r dis e a s e )
Ar t hr o s i s p a i n due t o
ha mme r t o e
Ca r p a l-t un n e l s yn dr o me
De Que r va i n dis e a s e
Me t a c a r p a l a n d
Me t a t a r s a l p a i n
Mo r t o n dis e a s e
Rhe uma t o id a r t hr it i s o f
ha n d/fo o t
H a n d/Fo o t t e n do n p a i n
due t o p r o l o n g e d

1 73
P.N.E.I.
a n t a l g i c
c o r e
An t i-
in fl a mma t o r
y c o r e
In fl a mma t o
ry p a i n
De g e n e r a
ti ve p a i n
REGULATION o f b–En do r p hi n
r e c e p t o r s
r e c e p t o r s
a n d IL1 b p r o -
a n d IL1 b p r o -
Pa i n mo dula t io n by
me a n s o f a c ut e
in fl a mma t io n
p he n o me n a – va s a l
in p a r t ic ul a r –
in hibit i o n (a r t hr o s is
typ e )
Pa i n mo dula t io n by
me a n s o f a c ut e
in fl a mma t io n
p he n o me n a – va s a l
in p a r t ic ul a r –
in hibit i o n (a r t hr o s is
typ e )
me a n s o f de g e n e r a t ive
p r o c e s s (a r t hr o s i s
typ e ) in hibi t i o n
me a n s o f de g e n e r a t ive
p r o c e s s (a r t hr o s i s
typ e ) in hibi t i o n
•Arn i c a mo n t a n a 4X
•Ca ulo p hil lum tha l i c t r o ide s 12X
•Le dum p a l us t r e 6X
•Be n zo i c um a c idum 6X
me a n s o f ur i c a c id
c r ys t a l s a c c umul a t io n
in hibit i o n (dra in a g e
a c t i o n )
me a n s o f ur i c a c id
c r ys t a l s a c c umul a t io n
in hibit i o n (dra in a g e
a c t i o n )
•Vio l a o do r a t a 6X
•Me r c ur ius s o lubi l i s 8X
•Cimi c i fug a ra c e mo s a 10X
Go ut
p a i n
GUNA®-H ANDFOOT

1 74
GUNA®-H IP
Clin i c a l
In dic a t io n s
H i p jo i n t
o s t e o a r t hr o s is
H i p jo i n t c a p s ule
in fla mma t io n
H i p jo i n t r he uma t o id
a r t hr i t is
H i p jo i n t p a i n o f
mus c le o r i g in
H i p jo i n t p a i n o f n e r ve
o r ig in (bur n i n g hip )
H i p jo i n t p a i n due t o

1 75
P.N.E.I.
a n t a l g i c
c o r e
H o me o p a t h
ic a n t a l g i c
c o r e
An t i-
in fl a mma t o
ry c o r e
Co n s t i t ut i o
n a l c o r e
An t i-
de g e n e r a t iv
e c o r e
r e c e p t o r s
r e c e p t o r s
a n d IL1 b p r o -
a n d IL1 b p r o -
Re duc t i o n o f hip
p a in s ymp t o ms o f
r he uma t ic o r ig in
:
• Ca p s ul e (Formicum
ac., Argentum)
• Te n do n s a n d
li g a me n t s (Rhus
tox)
• Ne r ve s
(Colocynthis)
• Mus c l e s (Arnica)
Re duc t i o n o f hip
p a in s ymp t o ms o f
r he uma t ic o r ig in
:
• Ca p s ul e (Formicum
ac., Argentum)
• Te n do n s a n d
li g a me n t s (Rhus
tox)
• Ne r ve s
(Colocynthis)
• Mus c l e s (Arnica)
• Bio s t imul a t io n o f
c a r t i la g in e o us ma t r ix
(Cartilago)
• Ne w ve s s e ls de ve l o p me n t
s t imul a t io n (Argentum)
• Bio s t imul a t io n o f
c a r t i la g in e o us ma t r ix
(Cartilago)
• Ne w ve s s e ls de ve l o p me n t
s t imul a t io n (Argentum)
•Arg e n t um me t a l li c um 6X
•Arn i c a mo n t a n a 8X
•Co l o c yn t hi s 8X
•Fo r mi c um a c . 8X
• Rhus to xi c o de n dr o n 10X
• Ca l c a r e a fluo r i c a 6X
• Co n s t i t ut io n a l
s t r uc t ur e p a t ho lo g y
• Co n s t i t ut io n a l
s t r uc t ur e p a t ho lo g y
• Ca r t i l a g o s ui s 4X
• Arg e n t um me t a l l i c um 6X
GUNA®-H IP

1 76
Clin i c a l
In dic a t io n s Sma l l jo in t s r he uma t o id
a r t hr i t i s o f ha n d a n d fo o t
Co s t o -s t e r n a l s yn dr o me
(Tie t ze s yn dr o me )
 Chr o n ic p o lya r t hr i t i s due t o
a ut o -immun e dis e a s e s (e .g .
Lup us e r yt he ma t o s us
s i s t e mic us )
 Br o ke n bo n e s yn dr o me due
t o vir a l o r p r o t o zo i c dis e a s e
 Jo i n t p a i n due t o c a n c e r
dis e a s e (c hr o n i c le uke mi a ,
mo n o c l o n a l blo o d dis e a s e s )

1 77
• Pa i n
En do r p hin
r e c e p t o r s
• Pa i n
En do r p hin
r e c e p t o r s
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
in fl a mma t o r y
a c t ivit y in the
in fl a mma t io n
ba s is
ba s is
lo c a liza t io n
lo c a liza t io n
•Le dum p a lus t r e 8X
•Vis c um a lbum 10X
P.N.E.I.
a n t a lg ic
c o r e
An t i -
in fl a mma t o
r y c o r e
Chr o n i c
in fl a mma t o r y
p a in
Ac ut e
in fl a mma t o r
y p a in
•Sa l yc i l ic um a c idum 2X
•Ac o n i t um 6X
•Dro s e r a 8X
•Co l c hi c um a ut umn a l e 10X
•Gua i a c um 10X

1 78
GUNA®-MUSCLE
Clin i c a l
In dic a t io n s
Tr i g g e r p o in t s
ma n a g e me n t : a c ut e ,
s uba c ut e , c hr o n ic
Fibr o mya lg i a s yn dr o me
Re fe r r e d s o ma t ic p a in
a r e a ma n a g e me n t
De r ma t o myo s it i s

1 79
Ac t i ve in g r e die n t s : Ar n i c a
mo n t a n a 4X H PUS, Co l o c yn t his 4X
H PUS 4 p a r t s ; Be ll a do n n a 6X
H PUS, Lit hium be n zo ic um 8X H PUS,
Mus c le t is s ue , Po r c i n e 4C,
Pr o c a in e c hlo r ide 2X 2 p a r t s ;
Co lc hic um a ut umn a le 6X H PUS,
Cup r um s ulp hur ic um 4X H PUS,
H yp e r ic um p e r fo r a t um 4X H PUS,
In t e r fe r o n g a mma 4C 1 p a r t .
In a c t ive in g r e die n t : St e r i le
is o t o n ic s o dium c hlo r ide
s o lut io n . © Dip a r t ime n t o Sc i e n t ific o Gun a S.p .a .

1 80
Co n t us i v
e p a i n
Sp a s t i c o r
c r a mp -l ike
p a i n
Sp r a i
n
p a i n
•In t e r fe r o n  4C
•Pr o c a i n c hlo r ide 2X
•Mus c l e tis s ue , Po r c i n e 4C
•Ar n i c a mo n t a n a 4X
•Be l la do n n a 6X
•Co lo c yn t his 4X
•Cup r um s ul p hur i c um 4X
• Co l c hic um a ut umn a l e 6X
•Lit hium be n zo ic um 8X
•H yp e r i c um 4X
Mus c ul a r
rhe uma t i s
m
An t i-
de g e n e r a t
ive c o r e
GUNA®-MUSCLE

1 81
GUNA®-NEURAL
Clin i c a l
In dic a t io n s
 No n -s p e c ific br a c hia l p a i n
 Br a c hi a l n e r ve p a i n due t o
c e r vi c a l e n t r a p me n t
 In t e r c o s t a l n e r ve p a i n due t o
t ho r a c i c e n t r a p me n t
 Po s t he r p e t i c n e ur i t i s
 Atyp ic a l fa c i a l n e ur i t i s (Slüde r
s yn dr o me , Cha r l i n s yn dr o me )
 Tr i g e min a l n e ur i t i s
 Pa i n o f t he t e mp o r o ma n dibul a r
jo i n t (TMJ)
 Ar n o ld s yn dr o me
Ce r vic a l, t ho r a c i c , lumba r a n d
s a c r o lumba r n e r ve r o o t p a i n

Manejo del dolor con medicamentos Guna

Manejo del dolor con medicamentos Guna

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Destaque

Destaque (12)

Semelhante a Manejo del dolor con medicamentos Guna

Semelhante a Manejo del dolor con medicamentos Guna (20)

Mais de Naturpharma (Medicina Biológica)

Mais de Naturpharma (Medicina Biológica) (20)

Último

Último (20)

Manejo del dolor con medicamentos Guna